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ABSTRACT 
 
AL-Marridi Wafa Z, Masters: 
June: 2018, Pharmacy 
Title: Pharmacoeconomics Evaluation of the Systemic Antifungal Posaconazole for Prophylaxis 
against Invasive Fungal Infections among Immunocompromised Cancer Patients in Qatar 
Supervisor of Thesis: Dr. Daoud Al-Badriyeh, PhD 
The immunocompromised hematologic malignancy patients, at the National Center 
for Cancer Care (NCCCR) in Qatar, receive the antifungal posaconazole for prophylaxis 
as systemic prophylaxis against invasive fungal infections (IFIs). No economic evaluations 
of the prophylactic posaconazole in Qatar exist in literature, whether about the resource 
utilization associated with posaconazole as a stand-alone therapy, or the comparative 
economic impact of posaconazole against potential alternatives. The objective of this study 
was to evaluate the pharmacoeconomic impact of prophylactic posaconazole in 
hematologic malignancy patients at risk for IFIs in NCCCR, Qatar. 
Methods. Decision analytic economic models to perform a cost-analysis and a cost-
effectiveness analysis of posaconazole were constructed. The decision analytic models 
were from the hospital perspective, to follow the therapeutic pathways and consequences 
of systemic antifungals for prophylaxis, for a study duration of 112 days. The primary 
endpoint was a success with no major adverse drug reactions (ADR). Prophylaxis failure 
was defined by IFIs occurrence, death, and IFIs prevention but with major ADR. The cost-
analysis model was based the medical records available from 2013 to 2015, at NCCCR of 
the Hamad Medical Corporation (HMC), but was also complemented by data extracted 
from literature and local expert panels. The cost-effectiveness model was based on 
 iv 
 
literature RCTs, which was adopted to the local setting by local expert panels and medical 
records data. 
Sensitivity analyses were conducted to enhance the robustness and generalizability 
of the results. 
Results. In the cost-analysis, 70 patients were eligible for the study inclusion. 
Therapy failure due to IFIs reached 43%, while death occurred in 7% of the patients, 
leading to successful prevention of IFIs in 50% of patients only. The primary outcome of 
IFI presentation without major ADR was achieved in 42.5% of patients. The average 
posaconazole utilization cost was QAR 109,802, with half of this consumed in failure due 
to IFIs. In the cost-effectiveness evaluation, similar success rate (IFI prevention without 
major ADR) was observed between posaconazole and fluconazole (0.76 versus 0.75, 
respectively), but with a significant Decremental Cost-Effectiveness Ratio (DCER) of 
QAR 3,922,618. The total therapy cost was higher with posaconazole (QAR 134,116 
versus 80,463).  The single patient pathway that influenced the outcomes of the models the 
most is the prevention of IFIs with having major ADR. Sensitivity analyses demonstrated 
the robustness of conclusions in both study models, with 96% chance for cost-savings to 
be in favor of fluconazole over posaconazole. 
Conclusion. The current study is the first economic evaluation of posaconazole in 
Qatar and the region, and the first in the literature to comprehensively follow up therapies 
throughout their IFIs failures and ADR. Prophylactic posaconazole was associated with a 
considerable cost to the NCCCR setting. This was considerably higher than that associated 
with fluconazole against IFIs in hematological patients, while being associated with a 
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marginally minor improvement in outcome. This contradicts local Qatari practices in 
relation to only having posaconazole available for the prophylactic use in NCCCR. 
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CHAPTER ONE: INTRODUCTION 
1.1. Clinical Overview  
1.1.1. Immunocompromised Patients and Hematologic Malignancy  
Patients who cannot resist infections due to a diminished or weakened immune 
system are defined as immunocompromised1. Here, being the primary identifier of low 
immunity, neutrophils cells play a critical role in protecting against infections. The 
damage to the immune system is mainly the result of disrupting the processes of 
chemotaxis and phagocytosis, compromising the neutrophil function, in eradicating 
intracellular pathogens from the body as the number of neutrophils subsides. Physicians 
define a case of neutropenia as an absolute neutrophil count (ANC) of 1500/microL or 
less. Neutropenia is considered severe if ANC is less than 500/microL, while moderate 
neutropenia falls between an ANC of 500 and 1000/microL2. Immediate pathogens 
(bacterial, fungal or viral) easily take advantage of such reduced immunity to attack and 
colonize to cause infections that are mostly of concern, especially if neutropenia is severe 
and lasting for a duration of above 7 days3. 
With the recognized increase in the number of immunocompromised patients, it is 
not surprising that the incidence of invasive fungal infections (IFIs) has been rapidly 
increasing over the last few decades4. The increase in the number of 
immunocompromised patients is best explained by the recent advancement in medical 
procedures and techniques, such as the increased exposure to intensive chemotherapy and 
radiation (as strategies for treating malignancies), or myelosuppressive therapies (for 
organ or bone marrow transplantations), which can significantly suppress immunity5. At 
the level of United States (US), as an example, the spread of cancer has increased 
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dramatically over the past decades to reach around 14.5 million cases in 2014, with an 
estimation to reach up to 19 million by 20246. Another contributing factor to the 
emergence of susceptibility is the excessive use of broad-spectrum antibiotics that over-
kill naturally colonizing bacteria, allowing for excessive growth of fungi. Also, there is 
overuse of corticosteroids, resulting in the elevated susceptibility to IFIs. Critical as well 
is the natural weakening of the immune system due to the normal aging process. 
Generally, with the advancements in healthcare and services, people live 40 years longer 
nowadays than in past decades, back in the 19th century7,8 . 
Patients with the hematologic malignancy of acute myeloid leukemia (AML), in 
particular, are at notably increased risk of infection, where the neutropenia associated with 
AML is considerably prolonged as compared to that in other cancers9. Apart from the 
disease, therapy itself, including chemotherapy and hematopoietic stem cell transplantation 
(HSCT), further increases the risk of severe neutropenia and, hence, increased 
susceptibility to the IFI as a life-threatening condition9. This is particularly important when 
taking into consideration how considerable the population of patients with the hematologic 
malignancy is. For example, there are approximately 20,000 new leukemia cases diagnosed 
every year in Europe, and about 99,000 existing patients being exposed to either 
chemotherapies or transplantation procedures for hematologic malignancies10. 
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1.1.2. Invasive Fungal Infection  
One major type of the IFI is the opportunistic infection type, which is diagnosed 
among populations with suppressed immune systems. Here, fungi pathogens are 
considered significant, causing systemic mycoses and invasive bloodstream infections11.  
In the Qatari setting, the causative fungi of most common IFIs are Aspergillus, Candida, 
Fusarium, and Scedosporium12,13. Table 1.1 summarizes the primary characteristics and 
consequences of these IFI-causative fungi in practices.  
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Table 1. 1 Clinical presentation of (and host reaction to) the most common IFI-
causative fungal species14 
Fungus Clinical 
presentation 
Host response Comment(s) 
Aspergillus Allergic 
bronchopulmon
ary aspergillosis 
Allergic mucous with 
eosinophils, Curshmann's 
spirals, Charcot-Leyden 
crystals; mucosa with 
suppurative and 
granulomatous inflammation, 
vasculitis, and fibrosis 
Hypersensitivity 
reaction to fungi, most 
frequently A. 
fumigatus; is 
commonly seen in 
patients with cystic 
fibrosis or steroid-
dependent asthma 
Allergic fungal 
rhinosinusitis 
Similar to that for allergic 
bronchopulmonary 
aspergillosis 
Hypersensitivity 
reaction to fungi that is 
similar to that for 
allergic 
bronchopulmonary 
aspergillosis 
Chronic 
pulmonary 
aspergillosis 
The wall surrounding the 
fungus ball consists of fibrosis 
Occurs in 
immunocompetent 
individuals with a 
variety of lung 
conditions 
(tuberculosis, 
emphysema, and 
others) in which the 
cavity or lesion is 
colonized and then a 
“fungus ball” or 
aspergilloma forms 
Candida Invasive disease Various inflammatory 
responses depending on 
immune status, primarily 
suppurative inflammation with 
rare granulomas, invasion of 
blood vessels, necrotizing 
vasculitis 
Occurs mostly as a 
healthcare-associated 
infection (patients with 
vascular access devices, 
with recent surgeries, 
receiving broad-
spectrum antibiotics, or 
immunosuppressed), 
can involve all organs 
Hyaline 
septated molds 
(Fusarium and 
Scedosporium) 
Similar to that 
for Aspergillus 
Some organisms have some 
peculiarities (for 
example, Scedosporium spp. 
are associated with pneumonia 
after near drowning) 
 
 
 5 
 
In one USA study, the prevalence of fungal infections between the late 1980s and 
early 2000s was investigated to demonstrate that while aspergillosis infections significantly 
increased by around 6%, the Candida infections decreased in occurrence by around 10%.  
An increasing rate of Fusarium and Scedosporium infections was noticed15, 16, 17. Here, the 
change in incidence of IFIs has been related to the change in the spectrum of pathogenic 
fungi18, 19. For example, aspergillosis has been spreading widely due to the fact that recent 
practices of managing patients with hematologic malignancies, particularly the spread of 
the prophylaxis against IFI, mainly targeted the Candida species infections. In one 
retrospective cohort study, in 2006, where patients with hematologic malignancies were 
followed from 1999 to 2003, aspergillosis was found to account for over 57% of all IFIs, 
while Candida was reported in 32% of IFIs20. 
Once a patient is infected, the IFI can be presented in highly variable clinical 
manifestations, related to the individual’s immunity level and physiological condition21. 
With invasive candidiasis, for instance, it is characterized by a rapid onset of fever that can 
reach shock beside other signs of sepsis. These clinical manifestations are not specific 
enough where it is seldom that definite clinical signs are accurately interpreted into correct 
diagnoses. As a result of such doubt, several tests and procedures are needed for making a 
definite determination of a diagnosis. This, however, disables the early diagnosis and, 
ultimately, delays receiving timely optimal management21,22. Required types of tests can 
range from the conventional mycological methods (direct microscopic examination and 
culturing of specimens), serological techniques (galactomannan test), to the radiological 
evidence (X-rays and high-resolution computed tomography, CT)21. 
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IFIs are life-threatening. Mortality rates remained unacceptable throughout the 
recent decades, reaching up to 90% of all proven IFIs23, 24. They shorten life and disturb its 
quality25. In Candida-related infections, the mortality rates reach over 30%, while the 
Scedosporium infections mortality is at approximately 58%. Higher mortality rates are 
associated with aspergillosis and the Fusarium infections, being 89% and 79%, 
respectively15,26.  
1.1.3. Antifungal Therapy  
The story began more than half a century ago, i.e. in the mid-nineties, when the first 
azole and polyene were isolated, followed by the discovery of amphotericin B in 1960. In 
the late 1980s, the new generation azoles (triazoles) fluconazole and itraconazole were then 
introduced27. Ten years later, in 1990s, terbinafine (an allylamine) was discovered28. By 
that time, the antifungal’s pharmaceutical market established its marked and steady growth, 
which was justified by the significant expansion in the number of immunocompromised 
patients27. However, the use of these diverse antifungal agents was still limited due to the 
insufficient spectrum of activity, drug resistance, toxicities and/or drug interactions29. 
Subsequently, pharmaceutical companies worked on producing more effective antifungal 
agents (or modified formulations), with improved tolerability of side effects. Amphotericin 
B was re-introduced in 1996 in a new liposomal formulation (liposomal Amphotericin B – 
LAMB),28 a new generation of echinocandins emerged in the early 2000s30, 31, 32, and the 
new triazoles voriconazole and posaconazole were later revealed in 2002 and 2006, 
respectively33,34. Very recently, in 2015, the Food and Drug Administration (FDA) had 
approved a new azole agent called isavuconazonium sulfate, which is a prodrug for 
isavuconazole35. 
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Overall, there is currently a total of four classes of systemic antifungal agents used 
for the management of IFIs. The classes are (i) polyenes (conventional amphotericin B and 
its lipid formulations), (ii) azoles (fluconazole, itraconazole, voriconazole, posaconazole 
and isavuconazole), (iii) echinocandins (caspofungin, micafungin, and anidulafungin), and 
(iv) allylamines (terbinafine)30. Table 1.2 describes the mechanism by which these agents 
work against fungi with an illustration of their chemical structure.  
 
 
Table 1. 2. A brief description of systemic antifungal agents’ mechanism of action, 
chemical structure, and the brand names available. 
Antifungal 
class 
Mechanism of action36 Agent Band 
name
37,38 
Chemical structure  
Polyenes  Depending on the 
concentration and the 
susceptibility of the fungi 
to this agent it could act 
as fungistatic or 
fungicidal. It acts by 
binding to the fungus cell 
membrane (specifically 
sterols) which leads to a 
disturbing the membrane 
permeability and leakage 
of intracellular 
components from the 
fungi cell and hence cell 
death.  
C
o
n
v
en
tio
n
al am
p
h
o
tericin
 B
 
F
u
n
g
izo
n
e  
A
m
p
h
o
cin
 
 
L
A
M
B
 
A
b
elcet 
A
m
b
iso
m
e A
m
p
h
o
tec 
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Cont. Table 1.2. A brief description of systemic antifungal agents’ mechanism of 
action, chemical structure, and the brand names available. 
Antifungal 
class 
Mechanism of action36 Agent Band 
name 
37, 38 
Chemical structure  
Azoles  Their action is 
fungistatic. They inhibit 
the fungal synthesis of 
ergosterol, through 
inhibition of an enzyme 
resulting in 
accumulation of sterol 
precursors which 
weaken the structure and 
function of the fungal 
cell membrane. 
F
lu
co
n
azo
le 
D
iflu
can
 
 
 Itraco
n
azo
le 
O
n
m
el 
S
p
o
ran
o
x
 
 
 Vo
rico
n
azo
le 
V
fen
d
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Cont. Table 1.2. A brief description of systemic antifungal agents’ mechanism of 
action, chemical structure, and the brand names available. 
Antifungal 
class 
Mechanism of action36 Agent Band 
name 
37, 38 
Chemical structure  
Azoles Their action is fungistatic. 
They inhibit the fungal 
synthesis of ergosterol, 
through inhibition of an 
enzyme resulting in 
accumulation of sterol 
precursors which weaken 
the structure and function 
of the fungal cell 
membrane. 
P
o
saco
n
azo
le 
N
o
x
afil 
 
 isav
u
co
n
azo
le 
C
resem
b
a 
 
 
Echinocandi
ns  
inhibits the synthesis of 1,3 
beta-D-glucan, a 
fundamental constituent of 
fungal cell walls, 
producing their fungicidal 
activity. 
C
asp
o
fu
n
g
in
 
C
an
cid
as 
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Cont. Table 1.2. A brief description of systemic antifungal agents’ mechanism of 
action, chemical structure, and the brand names available. 
Antifungal 
class 
Mechanism of action36 Agent Band 
name 
37, 38 
Chemical structure  
Echinocandi
ns 
inhibits the synthesis of 1,3 
beta-D-glucan, a 
fundamental constituent of 
fungal cell walls, producing 
their fungicidal activity. 
M
icafu
n
g
in
 
M
y
cam
in
e 
 
 An
id
u
lafu
n
g
in
 
E
calta 
 
Allylamines   Similar to azoles, it inhibits 
the biosynthesis of 
ergosterol. However, the 
agent has fungicidal action. 
T
erb
in
afin
e  
L
am
isil 
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1.1.4. IFI Management Strategies and the Need for Prophylaxis 
There are four strategies that are used to deal with IFIs, with the decision on each 
based on the patient health condition, results of clinical tests and the clinical 
manifestation39. Strategies are divided into the treatment of established fungal infections 
and the preventive strategy, with the latter further divided into three different approaches; 
prophylaxis, empiric, and preemptive therapies. For the preventative strategies, the patient 
will start receiving the prophylaxis once he/she is categorized as at high risk for infection. 
The empiric therapy is given to those who have persistent febrile (body temperature >37.5 
°c) neutropenia of unknown source that is unresponsive to antibacterial therapy, while the 
preemptive therapy aims at treating a suspected early IFI using radiologic and/or laboratory 
evidence rather than fever alone. As for the treatment pathway, the candidate should 
correspond to specific criteria such as the European Organization for Research and 
Treatment of Cancer/Mycoses criteria for identifying proven and probable infections39.  
It is a logical and more practical strategy to start providing prophylaxis therapy 
against IFI instead of waiting for the clinical manifestation to appear and the infection to 
develop, specifically with patients who suffer from hematological malignancies and 
receiving chemotherapies or undergoing HSCT, where infections are probable. The 
rationale behind choosing prophylaxis is that patients with low immune systems are at high 
definite risk for getting IFIs, added to that the mortality rate is high once a patient has IFI, 
and that the chance to cure the IFI is poor, added to the consideration that early diagnosis 
is difficlut, as discussed earlier 26,40. Also important to note is the substantial economic 
burden of the healthcare systems that are consumed into the treatment of established IFIs, 
where systemic antifungal agents are relatively expensive, and require prolonged 
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hospitalization. Here, there has been a considerable recent increase in the systemic 
antifungals costs, mostly the result of the emergence of newer agents that cover a broader 
spectrum of fungi, with improved formulations and/or enhanced safety profiles26 27.  
The prophylaxis indication first appeared in the international guidelines in the early 
2000s, but that was only in relation to limited cases of immunocompromised patients with 
hematological malignancies. Afterwards, however, with the emergence of newer antifungal 
agents, the awareness towards the antifungal prophylaxis concurrently increased 
worldwide, more relating the prophylaxis against IFI to a wider range of cancer patients. 
Recommendations were mostly evident by multiple randomized clinical trials in 
literature29, 41, 42. 
1.1.5. Guidelines on the Antifungal Prophylaxis Use in Hematologic Malignancies 
Based on the recommendations by the 2010 Infectious Diseases Society of America 
(IDSA) guidelines for the use of antimicrobial agents in neutropenic patients with cancer, 
along with the 2016 IDSA guidelines for the diagnosis and management of aspergillosis, 
there is an agreement that the newly diagnosed patients with hematologic malignancies, 
who are receiving chemotherapy for the first time or undergoing HSCT, and had or were 
anticipated to have neutropenia for 7 days or more, are stratified as at risk of IFI and, hence, 
are candidates for receiving systemic antifungal agents for prophylactic purposes42. The 
important elements for the anticipation of the IFIs are mostly related to the intensity and 
length of neutropenia. Based on the guidelines, a patient with an ANC of more than 700/ 
microL and an anticipated 5 days of neutropenia, for example, is considered at minimal 
risk for developing an IFI43.  
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1.1.6. Available Systemic Antifungal Agents for Prophylaxis. Advantages and 
Disadvantages 
Of all agents included under the four classes of antifungal therapy, only a few were 
approved for the prophylaxis indication. According to ISDA guidelines, fluconazole is the 
first line agent for prophylaxis when Candida is suspected. Fluconazole is available in oral 
and intravenous (IV) formulations and has tolerable side effects, with good drug-drug 
interaction profile and inexpensive generic cost. Drawbacks that are associated with the 
fluconazole administration include its narrow spectrum of activity against many Candida 
species, such as C. guillermondii, and C. lusitaniae,44 and the lack of activity against 
aspergillosis. Also, breakthrough infections due to fluconazole resistance are documented 
with regard to C. krusei and C. glabrata42. The triazoles itraconazole, voriconazole, and 
posaconazole are available in both formulations (oral and IV) and they are active against 
most fungi. They, however, have higher potential than other antifungals for interactions 
with specific chemotherapy medications, limiting their practical benefit in real practice. 
Voriconazole has a hepatotoxic effect, while taking itraconazole and posaconazole cause 
nausea, vomiting, fever, and headache events42. With regards to the newest triazole 
’isavuconazole‘, this is available in a water-soluble IV formulation, and its oral formulation 
has excellent bioavailability, with less drug-drug interactions than other triazoles. 
Nevertheless, it affects the hepatic function, added to the lack of enough supporting 
evidence, i.e. still in phase II trials in relevance to its prophylaxis use45,46,47. Echinocandins 
are another approved option for prophylaxis, which has a wider spectrum of activity than 
fluconazole, including covering aspergillosis, with enhanced safety profile. Nevertheless, 
these agents are highly costly and are only available in the IV form, which further adds to 
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the cost of administration given the need for hospitalization42. Both conventional and 
liposomal Amphotericin B are available as valid options, except that they are increasingly 
rarely used, due to the multiple problematic adverse reactions, e.g. nephrotoxicity, and the 
lack of evidence towards the prophylactic indication42,46,48,49.  
1.1.7. Status in Qatar 
In a local study of the prevalence of cancer in Qatar, between 1991 and 2006, 5,000 
persons were found to have diagnoses of cancer, with an annual incidence of 130 to 170 
cases50,51. The incidence of hematologic cancers, per 100,000 population, was 4.1 for males 
and 5 for females50. As for the mortality rate, hematologic malignancies alone accounted 
for 32% of death of all types of cancer52. 
Focusing on IFI, records over the period 2009–2014 reported around 300 
documented cases of candidiasis, with the annual mortality rate reaching a high 81.9%. 
Interestingly, only 11 cases of invasive aspergillosis were documented. Fusarium infection 
was also not common in Qatar, where 27 cases were reported. No reports of Scedosporium 
infections were found throughout the study period12. 
With regard to the use of prophylactic antifungals in the Qatari setting, i.e. at the 
National Centre for Cancer Care and Research (NCCCR) of the Hamad Medical 
Corporation (HMC), the main and only tertiary healthcare provider in the country, the 
strategy was first launched in 2006, where posaconazole was (and still is) used as the first 
line option, with fluconazole as an alternative when contraindications to posaconazole 
arise. In the NCCCR, candidates for prophylaxis therapy are those who are 
immunocompromised patients with hematologic malignancies and expected to have 
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neutropenia for >7 days, patients undergoing autologous or allogeneic HSCT, and patients 
receiving graft-versus-host disease therapy53,54,55. 
1.2. Economic Aspects of the Antifungal Therapy 
As discussed earlier, increased incidence of IFI will consequently increase the 
economic burden on healthcare systems. With the emergence of newer more expensive 
antifungal agents, which have efficacy and safety advantages over the older cheaper ones56, 
it becomes a must that the worthwhile of spending on the antifungals is evaluated against 
their relative outcomes, whereby spending resources on a particular preventive antifungal 
intervention can be characterized as a replacement of increased economic burden for 
reducing infections incidence. This is best described via economic evaluations, which 
compare the clinical outcomes and their costs among different available options57. Through 
this, decision makers ensure that the input resources consumed in a therapy achieve the 
maximal overall output. 
1.2.1. Pharmacoeconomics 
Pharmacy became recognized as a clinical discipline in the early 1960s, where sub-
disciplines such as clinical pharmacy, drug information, and pharmacokinetics constituted 
the most on demand disciplines of pharmacy education and sciences58.  The term 
‘pharmacoeconomics’ however, was first used 16 years later, in a published presentation 
that described the need for developing research activities regarding the evolving 
discipline58.  
Pharmacoeconomics is defined as the description and analysis of the costs of drug 
therapy to healthcare systems and society. This is an important science that is increasingly 
penetrating into the pharmaceutical literature. It identifies, measures and compares the 
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costs (i.e. resources) and consequences (i.e. clinical, economic, and humanistic outcomes) 
of pharmaceutical services and products58. In other words, pharmacoeconomics, as being a 
branch of economics, contributes to achieving efficiency in the use of medications 
regarding their costs and consequences. This is important for directing the use of limited 
resources to yield maximum benefit to both parties; patients and healthcare systems, in 
addition to the society as well59. Additionally, a cornerstone science that has become an 
integral of pharmacoeconomics is decision analytic modeling, which is a systematic 
approach that is used to simplify the decision making, where the therapy strategy is 
graphically represented, based on treatments and outcomes of interest, in what is called a 
decision tree. This assists decision makers to define the various options available in a 
treatment, define all possible outcomes and consequences of each option, calculate the 
probability of occurrence for each outcome, and calculate the economic value of each 
treatment option. This will definitly enable a decision making that is better informed60. 
Figure 1.1 shows a simple example of a decision tree of therapy options and 
consequences61.   
  
 
Figure 1. 1: A simplified illustration of a decision tree model of clinical pathways of 
available alternatives 
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As seen in Table 1.3, there are four types of pharmacoeconomic evaluations: (i) 
cost-effectiveness analyses (CEA), (ii) cost-benefit analyses (CBA), (iii) cost-utility 
analyses (CUA), and (iv) cost minimization analyses (CMA)57. Studies may utilize 
published clinical trials, existing medical records, decision analytic models or a 
combination of these to conduct the evaluation57. 
 
 
Table 1. 3. Summary of Pharmacoeconomics methodologies62. 
Method Description Application Cost Unit Outcome 
Unit 
CMA Finds the least 
expensive cost 
alternative 
Used when benefits are 
the same 
Monetary 
unit ($$$) 
Assumed to 
be equivalent 
CEA Compares alternatives 
with therapeutic effects 
measured in physical 
units; computes a cost-
effectiveness ratio 
Compares 
drugs/programs that differ 
in clinical outcomes and 
use the same unit of 
benefit 
$$$ Natural units 
CBA Measures benefit in 
monetary units and 
computes a net gain 
Compares programs with 
different objectives or 
units of benefit 
$$$ $$$ 
CUA Measures therapeutic 
consequences in utility 
units rather than 
physical units; 
computes a cost-utility 
ratio 
Compares 
drugs/programs that are 
life-extending with 
serious side effects or 
those producing 
reductions in morbidity 
$$$ Quality-
adjusted life 
years 
(QALYs)  
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While each pharmacoeconomic method having its advantages and disadvantages, 
CEA is the most commonly conducted in practices, for the following reasons58: 
a. Outcome units are measured in natural units, such as low-density lipoprotein 
cholesterol (LDL-C), millimeters of mercury (mmHg), years of life saved, or 
prevention of an event.  These are readily available in-patient records, which 
practitioners and decision makers are very familiar with.  
b. Clinical outcomes are not measured in money values, making the interpretation 
easier to the reader and researcher.   
c. Different therapeutic options with varying levels of outcomes can be compared, as 
long as outcomes are similar in nature. For example, one can compare the cost-
effectiveness among two or more alternatives for treating diabetes using the same 
outcome measure, which is the blood glucose level. A comparison between 
alternatives that handle different health conditions and, hence, have different 
outcome measures (e.g. glucose level for diabetes versus cholesterol level for 
hypercholesterolemia) is not possible to determine with the CEA design. 
On the other hand, the CEA method has its drawbacks58. 
a. Some scholars see CEA as being less comprehensive investigation compared to 
the CBA and CUA designs.  
b. Does not explicitly assure determining the economic value of human life, unlike 
CBA. 
c. Does not sufficiently address the humanistic dimension of outcomes, unlike the 
CUA.  
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d. Medications can only be compared against one indication at a time in the CEA. 
Comparing medications with multiple indications may require multiple cost-
effectiveness evaluations among the same medications. 
Advantages and disadvantages of the remaining methodologies are briefly 
discussed in Table 1.4. The pharmacoeconomic design of choice in an evaluation depends 
on the interest of researchers in the types of outcomes as well as the nature of the 
competitors involved.  
 
 
Table 1. 4. The main advantages and disadvantages of CMA, CBA, and CUA 
Pharmacoeconomics method Advantages  Disadvantages  
CMA Compares costs while 
assuming that outcomes are 
equivalent 
Limited application to 
intervention as finding a case 
of total equivalency is less 
likely to occur  
CBA Different outcomes can be 
compared since the outcome 
unit is unified (money value) 
No universal agreement on 
one standard method for 
valuing medical outcomes 
CUA Multiple outcomes can be 
compared, incorporates 
mortality and morbidity into 
one common unit without 
having to estimate the 
monetary value of the 
outcomes. Utility adjustment 
is also applicable  
The difficulty in determining 
an accurate utility or quality-
adjusted life year (QALY) 
value 
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Discussing costs, one should take into account that the cost of a therapeutic 
intervention is not its acquisition cost. The actual cost, in fact, comprises the value of all 
and any resources spent when the intervention was applied, including these associated with 
consequences 59,63. Further to costs in the pharmacoeconomic evaluations, there are four 
main types of costs: direct medical costs, direct nonmedical costs, non-direct costs, and 
intangible costs58.  Table 1.5 provides examples of each of the cost types58.  
 
 
Table 1. 5. Examples of the four types of costs used in pharmacoeconomics 
evaluations 
 Types of cost  Example 
Direct medical costs Medications, diagnostic tests, hospitalization, and patient’s counseling 
and education  
Direct nonmedical 
costs 
Travel costs to receive healthcare, nonmedical assistance related to 
condition (e.g. meals-on-wheels), and child care services for children 
of patients 
Non-direct costs Lost productivity for patient, lost productivity for unpaid caregiver 
(e.g. family member, friend) 
intangible costs Pain, suffering, fatigue, and anxiety  
 
 
 
1.2.2. Market Value of Antifungal Agents 
In the US, for example, the estimated antifungal market increased by US$1.2 billion 
within four years only (1999-2003). This was concurrent with the emergence of newer 
echinocandins and the triazole voriconazole. While the triazole posaconazole was not 
developed at that time, sales of azoles constituted more than half of the total market cost. 
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Globally, in 2012, the pharmaceutical market had a share of US$11.6 billion, consumed 
for systemic antifungal agents alone. In 2013, this share went even higher to reach US$11.8 
billion. By 2016 the global share was US$13.1 billion. This increase is expected to grow 
to up to US$13.9 billion by 2018 and, after that, in 2021, the market would reach US$16.1 
billion with a compound annual growth rate (CAGR) of 4.2% from 2016 to 202164,65. 
Moreover, back in the mid-1990s, the average cost of managing a case of 
aspergillosis in the USA was US$62,426, while the invasive candidiasis costs up to 
US$44,536 per case66,67. The value had been steadily growing, where, the estimated cost 
of treating IFI in the USA was US$65,001 per a case of aspergillosis and US$81,271 per a 
case of candidiasis in 201268. Although literature lacks information regarding the economic 
burden of IFI treatment in Qatar, therapeutic costs are expected to be at a similar trend to 
the international level. 
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CHAPTER TWO: LITERATURE REVIEW 
2.1. Pharmacoeconomics Studies: Prophylaxis Against IFI 
As emphasized in Chapter One, the incidence of IFIs has been on the rise over 
recent decades as it is associated with an increased risk for infections, especially among 
patients newly diagnosed with hematologic malignancies who are undergoing their first 
chemotherapy or HSCT.  
Given that this type of infection is accounting for elevated rates of morbidity and 
mortality, with a diagnosis that is difficult to detect, the prophylactic strategy against IFI 
is a reasonable practice that demonstrated improvement in outcomes69. A meta-analysis of 
randomized controlled trials (RCTs) concluded that using systemic antifungal prophylaxis 
was associated with a significant reduction in IFI and infection-related mortality among 
neutropenic patients receiving chemotherapy or undergoing HSCT70. Another rationale for 
prophylaxis strategy is the substantial economic burden on the healthcare system for 
treating established IFI. In 2005, a study in the Netherlands estimated a mean total cost of 
treating invasive aspergillosis that is approximately US$32,000 per patient with 
hematologic malignancy71. As for invasive Candida infection, the direct cost for 15 days 
of treatment is around US$5,000, despite not accounting for costs of treatment failure, 
antifungal switch, and other medical costs72. In recent years, higher costs were reported, 
wherein 2015, as an example, a cost-analysis of the expenditure of systemic antifungal 
agents in Turkey among patients with hematologic malignancies reported a total cost of 
US$1,271,789 (US$18,039 per patient)73. 
The increase in the cost of newer available choices for effective and safe 
prophylactic therapy has made it increasingly difficult and complex for physicians 
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nowadays to make decisions on agents for first-line use60,74. Indeed, while multiple clinical 
trials have revealed an apparent mortality reduction among patients at risk due to the 
utilization of broad-spectrum antifungal prophylaxis69, there is a literature controversy with 
following this approach due to the higher costs associated with these newer broad-spectrum 
agents, besides the issue of emerging drug resistance64,75,76. Hence, it is extremely crucial 
to apply pharmacoeconomics evaluations on the different prophylactic agents to aid 
making decisions that provide the best value for limited healthcare resources64.  
The following paragraphs chronologically provide a summary of relevant studies 
that were conducted among the hematologic malignancy populations, starting with a focus 
on studies investigating the necessity of the prophylaxis indication, mostly via triazole 
antifungals41,42. 
 Economic Evaluations of Prophylaxis Versus Placebo  
In 1995, a CBA was conducted through a double-blind, controlled trial to evaluate 
fluconazole as a prophylaxis therapy compared to no prophylaxis in patients with 
hematologic malignancies undergoing extensive chemotherapy. The study revealed that 
the net benefit was not statistically significant, where the incidence of 
systemic mycoses was unaffected (8/76 with fluconazole, versus 8/75). The study, 
therefore, concluded that fluconazole did not reduce healthcare costs77. However, a 
different conclusion was reported one year later, when Wakerly et al. performed a cost-
minimization analysis on two groups of patients; chemotherapy and HSCT recipients, to 
compare the cost consequences of prophylactic treatment using fluconazole alone, oral 
polyenes alone, a combination of both, and no prophylaxis. Authors concluded that 
prophylactic strategies are cheaper options than the ‘no prophylaxis’ approach. 
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Nevertheless, sensitivity analyses suggested that the most cost-beneficial approach 
depends on the underlying patient conditions as well as the data source used for drawing 
model probabilities78. The usefulness of prophylaxis was clearer in a Japan study, in 2006, 
when Nomura et al. compared the cost-effectiveness of fluconazole prophylaxis to the no 
prophylaxis option. Study data on resource use and costs were retrieved from hospital 
claims and Japanese reimbursement charges. The researchers confirmed that prophylaxis 
with fluconazole has clinical benefits along with favorable Incremental Cost-Effectiveness 
(ICER) Ratio of US$625/ year of survival79. 
Penack et al. were interested in evaluating the polyenes, not the triazoles, they 
conducted a CBA of low-dose LAMB prophylaxis versus no prophylaxis in 2007. The 
researchers utilized an RCT, with the economic data (i.e. medication and tests costs) 
obtained via German market prices and cost catalogs. This demonstrated that the use of 
LAMB prophylaxis in patients at high risk may result in significant cost savings compared 
with placebo reaching a net benefit of US$1,159 per patient80. 
In 2008, a decision analytic model was designed by de Vries et al. to assess the 
cost-effectiveness of itraconazole, fluconazole, versus no prophylaxis for hematology 
patients undergoing chemotherapy or HSCT as a preventative strategy against IFIs. 
Measures of failure to prevent IFI were extracted from a published meta-analysis while 
costs were derived from a national database. For both Netherlands and Germany, de Vries 
et al. concluded that itraconazole resulted in enhanced clinical outcomes with lower total 
costs reaching approximately US$5,300 per each IFI avoided. In fact, the probabilities that 
itraconazole dominated other options was 98% in both countries81. 
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 Comparative Economic Evaluations for Prophylaxis  
With the emergence of echinocandins, both Schonfeld et al. (2008)82 from the USA 
and Sohn et al. (2009)83 from Korea conducted cost-effectiveness studies of prophylactic 
micafungin versus fluconazole, where the time the need for prophylaxis was supported by 
guidelines. The latter relied on costs and life expectancy data from Korean sources, while 
Schonfeld et al. utilized clinical outcome data from published literature. The conclusions 
from both studies were similar, demonstrating micafungin as dominant for prophylaxis 
among cancer patients with HSCT. The difference in total hospital costs per patients was 
US$3,859 in the first study, where the second reported a cost savings of KW 95,511,000 
(US$1 = KW1,127.31).  
In 2011, Wilke performed a literature review of the pharmacoeconomics 
evaluations of echinocandins for treatment and prophylaxis indications84, whereupon 
reviewing 17 articles the author determined that of all echinocandins, only micafungin can 
be a cost-effective choice for prophylaxis, but only when fluconazole resistance was 
indicated. This led to the conclusion that echinocandins are probably not the first-line 
options for standard prophylaxis cases.  
Most studies were more interested in the comparative cost-effectiveness of triazoles 
(not polyenes and echinocandins) for prophylaxis. In between 2008 and 2010, four studies, 
by Stam et al.85, Collins et al.86, O'Sullivan et al.87, and Greiner et al.88, compared the cost-
effectiveness of posaconazole with that for standard azoles (itraconazole and fluconazole). 
The different studies were based on the same published RCT, by Cornely et al.89, in their 
analysis. While Collins et al. had considered cost per IFI avoidance as the outcome 
measure, the remaining three studies chose to expand their decision analytic models into a 
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Markov model, which allowed for the estimation of QALY gained85 or life years gained 
(LYG)87,88. The final conclusions obtained from the four studies were similar despite the 
different settings and countries of evaluations and the use of different outcome measures 
as per the researcher’s interest. The net result was that posaconazole is a cost-effective and 
cost-saving alternative compared to the standard azoles among neutropenic patients 
undergoing chemotherapy for treating the leukemia type of cancer. 
Following on the triazoles, Al-Badriyeh et al.90 performed the first CEA between 
two new triazoles, posaconazole and voriconazole, using a retrospective hospital chart 
review in Australia. The population of interest was AML patients in the induction stage of 
chemotherapy. The authors claimed that posaconazole was cost saving over voriconazole 
by US$13,400 per patient, due to lower rate of death with IFI and lower probability of 
discontinuation due to oral intolerance. The same research team then reported, by Heng et 
al.91, also in Australian patients with AML, utilizing medical records, that for the purpose 
of patients who are undergoing their consolidation stage of chemotherapy, fluconazole was 
the most cost effective over posaconazole and voriconazole.  Authors reported that 
fluconazole was 26% and 13% more cost saving over the newer azoles, posaconazole and 
voriconazole, respectively. That was mainly due to the higher rates of therapy success in 
fluconazole recipients. This was the first and only study that contradicts all previous 
economic studies on prophylactic posaconazole in literature, suggesting that fluconazole is 
better than posaconazole in some populations under especial local practices trends. 
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 Cost Analysis Evaluations of the Economic Impact of Prophylactic Antifungal Use 
While not comparative, the following studies, published within 2011 to 2015, were 
describing the costs and financial burden of systemic antifungals and medical resources 
utilized for prophylaxis indication.  
Imataki O et al.92  conducted a systematic simulation analysis in 2011 describing 
the medical cost analysis of systemic antifungal agents in Japan. The study was of fifteen 
RCTs, and considered probabilities of prophylaxis failure, need for empiric therapy, 
breakthrough infections, and incidence of side effects as outcome consequences. The 
estimated costs for prophylaxis and treatment of IFI was: oral itraconazole= US$1,035, 
oral fluconazole= US$1,552, micafungin= US$2,245, and US$3,028 for LAMB. The 
studies also accounted for costs of side effects and cost of infection management in case 
of therapy failure. 
In 2014, Heimann SM et al.69 performed a cost analysis of the direct medical costs 
of posaconazole and polyene in patients with AML. The study calculated costs consumed 
in the general ward and intensive care unit (ICU), including costs of mechanical ventilation, 
diagnostic procedures, all antimicrobial agents, and staff involvement. Posaconazole cost 
US$22,517 per patient, while this was lower with polyene (US$24,795). The primary cost 
driver in favor of posaconazole was the shorter length of stay and ICU treatment. 
In 2015, Gedik H5 published a retrospective study describing the expenditures 
associated with using systemic antifungal medications for both treatment and prophylaxis 
purposes among patients with hematologic malignancies in Turkey. The antifungal agent 
that cost most was LAMB, given for the treatment purpose, with an average cost per month 
of US$29,322 and a total cost per year of US$366,537; followed by caspofungin 
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(US$28,410 per month and US$355,125 annually). Posaconazole and fluconazole were 
used in the study for primary and secondary prophylaxes, respectively. Posaconazole costs 
US$337,757 per year, and the annual total cost of voriconazole was US$177,230 for the 
IV formulation and US$34,951 when orally administered.  
Also, in 2015, Ceesay et al.93 summarized the economic burden of systemic 
antifungal use among patients with different hematologic malignancies. The study included 
patients from King’s College Hospital in London through a cohort design considering the 
perspective of the hospital for cost analysis. It was declared by the authors that the variation 
in total costs of IFI is associated with factors such as primary diagnosis, core hematologic 
treatment, and IFI status (i. e. proven, possible, no evidence). Considering prophylaxis 
costs only, AML patients cost over US$5,000 per patient while myeloma patients cost the 
least (US$850 per patient). Prophylaxis in patients who received allogeneic HSCT cost 
US$5812, and this was US$1147 in the autologous patients. As for patients with proven 
IFI after prophylaxis, the prophylactic strategy cost was US$4,535 compared to US$2,755 
spent for patients with no IFI developing. 
 Core Message of Literature Studies  
As seen above, treatment options that are eligible to use in prophylaxis were 
economically evaluated in different types of hematologic malignancies. In earlier studies, 
the evaluations were mostly of prophylaxis versus none. Afterwards, the need for 
prophylaxis was deemed definite in literature, and studies more focused on how newer 
prophylactic antifungals agents (i.e. micafungin, posaconazole) economically compare to 
older agents71.  
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To recap, economic evaluations of systemic antifungal agents for prophylaxis in 
immunocompromised patients with different hematological malignancies demonstrated 
favorable potential. However, it is difficult to specify a single prophylactic agent as 
superior. The generalizability of economic evidence is not clear due to much variability in 
several factors of consequence in the economic evaluation. As one main of such factors, 
patients with hematological cancer can be categorized according to the main treatment 
received; (i) chemotherapy and (ii) HSCT, whereby the underlying disease and its therapy 
have an influence on the immunity level, which consequenty influence the occurrences of 
IFI71. Other important factors that limited the generalizability relate to the (i) type of 
pharmacoeconomic evaluation used (i.e. cost analysis, cost-effectiveness, cost-benefit), (ii) 
time horizon to follow patients, (iii) study perspective (i.e. hospital or payer), (iv) outcome 
measure and its definitions, and (v) cost data71.  
2.2. Study Rationale and Significance  
As indicated in Chapter One, posaconazole was and still the only first-line 
prophylactic antifungal used in NCCCR in Qatar. No economic data or a local evidence on 
the use of systematic antifungals in Qatar was ever generated at any level. There is, 
therefore, a need for a Qatari-based research that aims at analyzing the cost of the currently 
used prophylactic antifungal in use at the NCCCR in Qatar, i.e. posaconazole, among 
newly diagnosed hematologic malignancy patients, including as compared to fluconazole, 
a potential alternative antifungal that is widely recommended for first-line prophylactic use 
in AML settings91,94,95.  
There is no information on the economics of using systemic antifungals in cancer 
patients, not only in Qatar, but regionally, including as prophylaxis. This includes any 
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reports of resource utilization about the antifungals in general. Evaluating the impact of 
posaconazole on resource consumption is most important for better understanding its 
impact on hospital budgets for decision makers and practitioners to consider, beyond the 
acquisition costs only. This includes understanding the economic impact of the clinicians’ 
handling practices of side effects, or their handling strategies of discontinuations. Such 
information can certainly be useful for decision makers and clinicians alike when 
considering and revising their protocols and practices in Qatar. 
Evaluating the comparative value of posaconazole will also be significant as, 
internationally, there are conflicting reports on the economic usefulness of posaconazole 
against other commonly used systemic antifungals in practice, e.g. fluconazole85,91,96,97. 
Especially that posaconazole and fluconazole are the most widely used antifungals among 
immunocompromised hematologic malignancy patients. The value of the comparative 
evaluation of posaconazole from the local perspective cannot be underestimated, which is 
due to, as already discussed earlier, how locally specific and not generalizable the 
pharmacoeconomics studies are. For example, while, as per most international practices, 
alternative prophylactic antifungals are administered to patients in cases of 
discontinuations due to side effects, the practice in Qatar is that the prophylactic 
administration of an antifungal is stopped until the side effects resolve, before the initial 
antifungal is re-administered.  
In all economic litearture of posaconazole, cost-effectiveness studies were 
conducted to justify the use of an expendive drug over cheaper older ones85,91.96.97. The case 
of the Qatari practice is different, however; whereby, posaconazole, due to general 
evidence of supoeriority, is the first and only prophylaic antifungal that NCCCR ever had 
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and used in hematology patients. Here, the future research question would be about how 
much an alternative that is associated with slightly less effectiveness, but much reduced 
cost, would produce in cost saving over posaconazole in the NCCCR. The only 
prophylactic antifungal agent that demonstrated to be non-inferior to posaconazole is 
fluconazole. To figure out how much cost saving the NCCCR setting would achieve by 
replacing posaconazole with fluconazole is a most important component of working to 
comprehensively, comparatively understand the value of posaconazole.  
While the economic evaluations of systemic antifungal agents are exponentially 
increasing in literature nowadays to support answering questions on best choices of therapy 
from the clinical and economic point of views60, there is no information on how this science 
is utilized and/or its strengths and weaknesses with regards to systemic antifungal agents 
that are used among patients at risk of IFI. Indeed, the quality of methodologies utilized to 
conduct economic evaluations within this context has not been evaluated yet, including for 
the guiding of further future economic evaluations in the field of focus98. Here, systematic 
reviews are one of the common valuable types of journal publications. They are a vital 
requirement to ensure evidence-based medicine statements. In the context of 
pharmacoeconomics research, however, it is doubtful that such statements are as reliable 
and robust as those made in the context of clinical research99,100. As discussed earlier, the 
economic evaluations are difficult to generalize due to high variability in setting practices, 
methods used, input data, and affordability. Hence, within the context of economic 
evaluations of systemic antifungal agents used as a preventative strategy against IFI, a 
systematic review of the literature to answer questions about characteristics and quality of 
research of systemic antifungal agents in patients with hematological malignancies, 
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including the strength and limitation of methodological aspects used, will be valuable. 
Identifying literature methodological characteristics and trends will work to identify 
methodological gaps and practical recommendations for the researchers to consider in 
planning and organizing their future research in settings. In addition, decision makers 
would have a better understanding of the quality of generated evidence as they would be 
able to contrast it against the current strengths and weaknesses of methods in the literature. 
2.3. Study Objectives 
Mainly, this research looks at generating information that would direct the efficient 
delivery and management of posaconazole for prophylaxis against IFI in hematologic 
malignancy patients undergoing chemotherapy or HSCT in the local Qatari setting. It will 
be significant to conduct an economic analysis in the local Qatari setting where resources 
are scarce and/or infectious disease (ID) departments are busy and hazardous, such as in 
the ID department at the NCCCR. The more the cases of successful prophylaxis against 
IFI, the fewer occasions for getting invasive infections, which results in a reduced need for 
exposing the patient to further expensive systemic antifungals for treating such infections 
that is of high mortality rates. In addition, since the current clinical practices in Qatar can 
be different from in other settings, it will be inappropriate to assume that using other similar 
studies in literature is valid for guiding the Qatar settings when it comes to impact on cost 
and, therefore, local economic evaluations of posaconazole are indeed needed.  
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The research in the thesis was therefore undertaken via two phases:   
Phase 1: Pharmacoeconomics Evaluations of Posaconazole 
A comprehensive economic assessment of the utilization of posaconazole for 
prophylaxis against IFI among immunocompromised patients with hematological 
malignancies, who are receiving chemotherapy or undergoing HSCT at the NCCCR in 
Qatar. This was conducted through the following two evaluations; 
 Evaluation 1: Cost-analysis of the overall resource utilization associated with the 
prophylactic use of posaconazole. 
 Evaluation 2: Cost-effectiveness analysis of the comparative economic value of 
posaconazole against fluconazole. 
Phase 2: Systematic Review of Methodological Trends and Gaps, and the Reporting 
Quality of Comparative Economic Evaluations on the Use of Systemic Antifungal 
Agents Used for Prophylaxis Against IFI 
Adding to the conclusions made via phase 1 of the thesis, recommendations for 
relevant future research are made based on a comprehensive systematic review that was 
conducted to summarize the quality of the methodological aspects, including strength and 
weaknesses, of the comparative economic evaluations on the use of systemic antifungal 
agents used for prophylaxis against IFI in immunocompromised patients with hematologic 
malignancy, who are undergoing chemotherapy or HSCT.  
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CHAPTER THREE: MATERIALS AND METHODS 
3.1. Phase 1: Pharmacoeconomics Evaluations of Posaconazole  
As per the study objectives of phase 1, methods of the study relate to two different 
evaluations that will be discussed separately. 
3.1.1. Evaluation 1: Cost-Analysis of the Overall Resource Utilization Associated with 
the Prophylactic Use of Posaconazole 
This is to perform a cost analysis simulation model of using the systemic antifungal 
agent posaconazole as indicated for the prophylaxis against IFIs among patients with 
hematological malignancies in the NCCCR ,in Qatar.  
3.1.1.1. Model Structure  
An economic model was constructed to follow posaconazole’s use and potential 
consequences of interest as prophylaxis in patients with hematologic malignancies, as 
illustrated in Figure 3.1. 
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The model included three possible outcome pathways on whether the prophylactic 
therapy was successful, and, if not, for what reason. Therapy success was defined as 
survival with the absence of proven/possible/probable IFIs within 112 days (4 months) of 
receiving the first does of prophylaxis while patients are under their chemotherapy cycle 
or undergoing a HSCT. The duration of follow up is consistent with the relevant literature 
evaluations of systemic antifungal agents for prophylaxis purpose, whereby relevant drug 
outcomes are considered to be those who are reported by 3 to 4 months of starting the 
prophylaxis therapy. IFI is anticipated to appear as soon as few weeks only among the 
chemotherapy and HSCT immunocompromised patients86,101,102. 
  A successful therapy can be associated with major adverse drug reactions (ADR), 
minor ADR, or no ADR. Major ADR are ADR that lead to therapy discontinuation, while 
minor ADR do not. Failure of therapy was due to termination of prophylaxis because of 
Figure 3. 1: Economic model of posaconazole use as prophylaxis in hematologic 
malignancies 
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proven/possible/probable IFIs or because of death during the follow up duration. In case of 
IFIs and taking in consideration that type of the causative fungi, patients are switched to 
another licensed systemic antifungal agent for the treatment purpose. All alternative 
therapies were assumed to be successful. 
3.1.1.2. Ethical Approval  
The required NCCCR ethics approval was obtained via the ethics committee of 
Medical research Centre (MRC) in HMC, Qatar. (See approval letter in Appendix 1). Due 
to its retrospective nature, the current research was exempted by Qatar University from full 
ethics reviews (Appendix 2). 
3.1.1.3. Patient Population  
Inclusion Criteria: 
1. Patients admitted to the hospital between 1st January 2013 and 31st December 2015  
2. Patients with hematologic malignancy and received chemotherapy or HSCT in 
Qatar  
3. Patients who received systemic posaconazole prophylactic therapy against IFI, with 
a standard dosing of 200 mg suspension, three times a day 
4. Patients who did not receive any systemic antifungal agents within the 7 days prior 
to commencing the prophylactic therapy  
5. Patients with no current or previous history of IFI 
Exclusion Criteria: 
1. Patients who are 15 years old or below 
2. Patients who received a hematology treatment in overseas 
3. Patients with previous history of IFI 
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4. Patients who were exposed to systemic antifungal agents within 7 days of receiving 
their antifungal prophylactic agent 
5. Patients with a non-malignancy hematologic disease and a solid organ cancer 
3.1.1.4. Study Perspective  
  The economic model was constructed to adopt the hospital perspective of NCCCR 
in Qatar, where only resources with direct medical costs were considered, including 
diagnostic and monitoring tests, prophylactic medical therapy, medications for managing 
ADR and IFIs, hospitalization, and duration of therapy. Only the resources in relevance to 
the prophylactic use of posaconazole and its consequences were considered. Direct medical 
costs associated with the patients’ underlying diseases were not incuded. Due to the 
retrospective nature of data sources and perspective of the study, intangible and direct non-
medical costs were also not included in the study. 
3.1.1.5. Model Resource and Clinical Inputs and the Data Collection  
The simulation model inputs were mainly derived from the electronic medical 
health records of the NCCCR, since the inception of the Cerner® a medical database at the 
hospital. A data collection form, seen Appendix 3, was utilized to extract relevant data of 
interest from the records. Data collected through medical records related to probabilities of 
success, failure and death, patients’ demographics, the underlying diagnosis, other 
diseases, antifungal prophylaxis, duration of therapy, laboratory and microbiological tests, 
concurrent medications, and mortality status. For a patient, medical records data were 
collected throughout 112 days duration from prophylaxis onset. 
ADR reporting in medical records is not comprehensive and mostly inaccurate. 
Probabilities of ADR, therefore, were obtained from the published clinical trial by Ullmann 
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et al103. This is a large published clinical trial that, like in the current study, evaluated 
posaconazole as prophylaxis in hematological malignancy.   
Due to the limited patient sample size and an anticipated missing data in relation to 
the identification and management of IFIs, an NCCCR-based independent expert panel was 
created to provide information on the frequently identified IFI causative fungi in NCCCR 
and the strategies used to manage them along with ADR. The panel comprised a specialist 
senior clinical pharmacist and three hematology and infectious diseases specialist 
clinicians, who also had personal clinical experiences with the systematic fungal therapy 
in NCCCR. The expert panel provided data via meetings, where answers to questions were 
discussed until consensus. In preparation for meetings, all questions and required 
information were circulated to panel members. A list of questions to the expert panel can 
be seen in Appendix 4.  
The expert panel was also asked to discuss the structure of the economic model and 
validate it. 
3.1.1.6. Cost Calculation  
All costs accounted for the study were calculated in Qatari Riyal (QAR) for the 
financial year 2016/17, and no discounting was performed due to the short-term duration 
of follow up.  
The cost of initial prophylaxis was the cost of a complete course of posaconazole 
until success or death, or until switching to alternative therapies due to major ADR or 
occurrence of infection that require tailored treatment. The cost of alternative therapy was 
the cost of a complete course of the alternative agent. This is based on the assumption that 
if patients switched therapy after prophylactic failure, the subsequent alternative therapy 
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was successful. With a similar trend, the cost of managing minor ADR was also the cost 
of a complete course of treatment for the drug event. The overall cost of a patient is the 
initial cost and any alternative therapies added to the cost of resources consumed for 
monitoring and screening tests throughout the duration therapy. 
Medication costs used were the wholesale drug prices as derived from the 
MyCare® pricing system, which is the local pricing database at the NCCCR. Doses for all 
medications were rounded to the nearest vial size. As per the routine clinical practice at 
HMC in Qatar, patients were not allowed to share the same posaconazole bottle. Cost of 
diagnostic and monitoring testing and the hospitalization stay associated with patients with 
hematologic malignancies was obtained from the department of finance, NCCCR. Patients 
receiving prophylaxis were treated as outpatients throughout the study period. Only when 
the patient had a failure of therapy due to IFI, hospitalization costs were accounted for. 
All resource costs were inflated to 2016/17 values as per the 2017 Qatari Consumer 
Price Index (CPI).  
3.1.1.7. Sensitivity Analysis 
To assess the robustness of the study conclusion, study outcomes were evaluated 
via sensitivity analyses against variations in the values of key variables, related to 
deterministic and probabilistic inputs. Sensitivity analyses were performed using one-way, 
scenario and multivariate analyses. 
One-way sensitivity analysis was conducted on hospitalization costs, the 
occurrence of major ADR, and the accountability for the cost of diagnostic tests, which 
may not necessarily relate the antifungal use in patients. The scenario analysis evaluated 
the impact of the hypothetical scenario of having patients sharing their posaconazole 
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bottles in therapy. Based on the Monte Carlo analysis, as described below, the probability 
cost of therapy was also generated in consequence to ±20% undertainty in drug prices. 
Monte Carlo uncertainty and probabilistic analysis via @Risk-5.7® (Palisade 
Corporation, NY, USA) was also performed, to generate probability measures of cost 
oucomes and to rank variables as per their influence on final study outcomes. Monte Carlo 
is a method that allows for multiple model simulations to run, each time sampling inputs 
from pre-defined uncertainty ranges of input values. Here, with 10,000 iterations and a 
triangular type of input distribution used, a ±5% uncertainty range was assigned to the 
probability data obtained via the expert panel, i.e. probabilities of causative fungi 
accurance, while all other model probabilities varied by a ±3% uncertainty range.  
3.1.2. Evaluation 2: Cost-Effectiveness Analysis of the Comparative Economic Value 
of Posaconazole Against Fluconazole 
This is to perform a cost-effectiveness analysis model of the use of the systemic 
posaconazole compared to fluconazole in the prophylaxis against IFI among cancer 
patients with hematological malignancies in NCCCR in Qatar.  
3.1.2.1. Model Structure 
A decision analytic model was constructed to capture downstream consequences of 
prophylactic posaconazole versus fluconazole in patients with hematologic malignancies 
as illustrated in Figure 3.2. 
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For posaconazole and fluconazole, identical model pathways were followed. A 
successful prophylaxis is that not associated with proven/possible/probable IFIs or death 
during the patient follow up in the Ullmann et al. trial103, i.e. 112 days of receiving the first 
dose of prophylaxis while on undergoing chemotherapy or HSCT. Prophylaxis can be 
successful and associated with major ADR, minor ADR, or no ADR. ADR that lead to 
therapy discontinuation are considered major, and those that do not are minor. 
Prophylaxis failures if proven/possible/probable IFIs or death occurs during follow 
up. As per the Ullmann et al103. trial, an identified IFI is the result of Aspergillus, Candida, 
Figure 3. 2. Decision analytic model of prophylactic antifungal therapy in hematologic 
malignancies 
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or Fusarium fungi. As a consequence to an IFI, a patient  was assumed to switch to another 
licensed systemic targeted antifungal therapy.  
3.1.2.2 Ethical Approval 
As discussed under 3.1.1.2 the required ethics approval was obtained as appropriate 
via the MRC of HMC. As was also discussed, the research was exempted by Qatar 
University from the full ethics committee review.  
3.1.2.3. Study Perspective  
The economic model adopted the hospital perspective of NCCCR. Only direct 
medical costs were considered, including costs of diagnostic and monitoring tests, 
prophylaxis therapies, medications for managing ADR and IFIs, hospitalization, and 
duration of therapy. Only the resources in relevance to the prophylactic use of 
posaconazole and fluconazole were considered. Intangible and non-medical costs were not 
included in the study.  
3.1.2.4. Model Input  
Input model data that were primarily derived from the Ullmann et al103. trial 
included propabilities of the different health states and the duration of therapy with each, 
Vide Infra in Chapter 4 of the thesis.  
Based on the trial, patients on posaconazole suspension received 200 mg three times 
a day, and fluconazole was administered as capsules of 400 mg once daily throughout the 
treatment duration, which is all identical to the administration of these in the Qatari setting. 
To adopt the economic model to the local Qatari setting, an independent expert 
panel was arranged from the perspective of NCCCR, comprising a specialized senior 
clinical pharmacist and three consultant clincians with clinical expertise in systemic fungal 
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therapy and specialist knowledge in hematology and infectious diseases. The panel 
provided required data about the patient management in Qatar, which were not available 
from the literature, Vide infra in Chapter 4. Data included screening and monitoring tests 
conducted in relevance to the IFIs, in addition to strategies of managing the different ADR 
and IFIs, which included what the major ADR and IFIs in the local setting are. Before the 
meetings, members of the panel were provided with a list of questions of interest, added to 
a copy of the trial manuscript by Ullmann et al103. During the meeting, time and 
opportunities to discuss were given to members until consensus was achieved.  
The expert panel was also asked to discuss and validate the decision tree of the 
study model. 
3.1.2.5. Cost Calculation  
Costs were calculated in QAR for the financial year 2016/17, with no cost 
discounting performed.  
The cost of initial prophylaxis was the cost of a complete course of posaconazole 
or fluconazole until success, death, or until switching to alternative therapies due to major 
ADR or IFIs. The cost of an intervention due to the ADR or IFIs is the cost of a complete 
course of the intervention. Here, it is assumed that when patients are given interventions 
due to ADR or IFIs, the intervention is successful. The cost of each treatment outcome was 
the cost of initial and interventional therapies, added to the cost of resources consumed. 
Regardless of the outcome, patients were analyzed according to the group that they were 
initially assigned to. 
Medication costs used were the wholesale drug prices as derived from the 
MyCare® pricing system, which is the local pricing database at the NCCCR. Doses for all 
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medications were rounded to the nearest vial size. As per the routine clinical practice at 
HMC in Qatar, patients were not allowed to share the same posaconazole bottle. Cost of 
diagnostic and monitoring testing and the hospitalization stay associated with patients with 
hematologic malignancies was obtained from the department of finance, NCCCR. Patients 
receiving prophylaxis were treated as outpatients throughout the study period. Only when 
the patient had a failure of therapy due to IFI, hospitalization costs were accounted for. 
All resource costs were inflated to 2016/17 values as per the 2017 Qatari CPI. 
3.1.2.6. Sensitivity Analysis 
To assess the robustness of results, sensitivity analyses were performed via one-
way, scenario and multivariate analyses. Costs have a potential impact on the study 
outcome and, hence, variation in costs was investigated via the one-way sensitivity 
analyses. This included costs of antifungal agents (±20%) and cost of hospitalization 
(±100%) added to the duration of hospitalization. Investigating the overall cost without 
accounting for costs of diagnostics tests, and only accounting for the regular monitoring 
tests, was conducted, given the lack of relevance to the fungal therapy. Key deterministic 
and probabilistic data provided by the expert panel are associated with uncertainty and 
were also assessed. Scenario analysis was also performed by evaluating the case of 
changing the practice to the sharing of posaconazole bottles between patients.   
Probabilistic sensitivity analyses using Monte Carlo simulation was performed via 
@Risk-5.7® (Palisade Corporation, NY, USA) to test against uncertainty. As previously 
discussed, Monte Carlo is a method that enables multiple model simulations, using pre-
defined uncertainty ranges of input values. A triangular type of distribution was performed 
with an uncertainty range of 0-100% associated with the probability of prophylaxis failure 
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due to possible infection, to account for potential high variability in infection epidemiology 
among different settings. An uncertainty of ±5% was assigned to all other outcome 
probabilities in the model. The uncertainty analysis was based on 10,000 model simulation, 
with the corresponding costs calculated, and a probabilistic distribution of cost outcomes 
obtained. The study variables that influence the overall cost outcomes the most were also 
determined.  
3.2. Phase 2: Systematic Review of Methodological Trends and Gaps, and the 
Reporting Quality of Comparative Economic Evaluations on the Use of Systemic 
Antifungal Agents Used for Prophylaxis Against IFI 
This is a systematic review of all pharmacoeconomics publications on the use of 
systemic antifungal agents for prophylaxis against IFI among immunocompromised cancer 
patients in the English-language medical literature until Jan 2018. The study was to review 
the characteristics, methodological trends and gaps, and the reporting quality of literature 
research. This will enable the consolidation of conclusions made in Phase 1 of this thesis 
with recommendations to enhance future research on the topic of antifungal prophylaxis.  
3.2.1. Literature Review 
 The electronic databases Pubmed database, Embase database, Economic evaluation 
database, Econlit database, Cochrane Library, and Medline database were utilized to search 
relevant literature. The search strategy included three main domains; the therapy, disease, 
and research design. Search indices included the MeSH terms "Antifungal Agents"[Mesh], 
"Pre-Exposure Prophylaxis"[Mesh], "Mycoses"[Mesh], Fungal"[Mesh], 
"Immunocompromised Host"[Mesh], "Neoplasms"[Mesh], "Cost-Benefit 
Analysis"[Mesh], "Economics"[Mesh], "Costs and Cost Analysis"[Mesh]. Keyword terms 
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included prophylaxi, Lung diseases, systemic, invasive. The search strategy via PubMed is 
in Appendix 5, which was adapted for other databases.  
3.2.2. Inclusion and Exclusion Criteria 
Inclusion Criteria: 
1. Literature publications were included until January 2018. No considerations were 
made of whether articles are freely available 
2. Therapy based comparative studies. No considerations were made of whether 
studies are retrospective or prospective 
3. Studies of systemic antifungal agents for the prophylaxis indication 
4. Studies of undelying immunocompromised cancer patients at risk of IFI 
5. Pharmacoeconomics studies 
Exclusion Criteria: 
1. Non-English language 
2. Non-human studies 
3. Non-comparative research, e.g. letters, general reviews, editorials 
4. Studies on topical antifungal agents and/or non-invasive fungal infections 
5. Non-economic based studies 
 Data Collection and Handling  
 Screening for initial eligibility via the search terms was by assessing the title and 
abstract first. Articles that were found via the database search were further screened for 
eligibility by manual analysis of study abstracts. Then, for final inclusion in the study, a 
follow up manual screening by reviewing the full text of the initially eligible articles was 
conducted. This process, in addition to data extraction, was separately performed for 
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conformance by each of investigators. Disagreements were further discussed by the 
research team as led by a third investigator. Before formal data extraction, and for 
validation purposes, a random sample of three included articles was independently 
reviewed by each of the study investigators before discussed to ensure consistency and 
agreement among all. 
 Extracted data from included full texts related to study characteristics and 
methodological features, incuding general paper information (authors, year of publication, 
publishing journal, method of economic evaluation, drugs compared, country, population 
of underlying disease, participants age, sample size); clinical effectiveness component 
(study setting, clinical measure definition, source of effectiveness data, time horizon of 
follow up, clinical outcome results); economic effectiveness component (perspective, 
study setting, date of analysis and date of economic data, time adjustment type, source of 
economic data, modeling type and pathways used, type of costs considered, measure of 
benefit used; and study results (sensitivity analysis outcome, statistical analysis used, main 
economic findings, authors conclusions). 
 A template of the developed data extraction form is supplemented in Appendix 6. 
All investigators have training in pharmacoeconomics research. Descriptive statistics and 
tabulations were used to present results. The PRISMA checklist (Appendix 7) was followed 
for completing the systematic review. 
3.2.3. Quality Assessment 
A reporting quality assessment was of the pharmacoeconomics studies was 
performed by using the Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) checklist (Appendix 8)104. While there are other available checklists for the 
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economic evaluations, the objective of the quality checklist was not to investigate bias for 
evidence generation but to guide the content description of articles, where CHEERS is 
considered most comprehensive and appropriate. The quality assessment was 
independently conducted by the different individual investigators, as described above.  
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CHAPTER FOUR: RESULTS  
4.1. Phase 1: Pharmacoeconomics Evaluations of Posaconazole  
As per the study objectives, results of this phase of the study relate to two 
different evaluations that will be described separately. 
4.1.1. Evaluation 1: Cost-Analysis of the Overall Resource Utilization Associated with 
the Prophylactic use of Posaconazole 
4.1.1.1. Eligible Patients and Underlying Malignancies  
A total of 70 eligible patients, admitted to the NCCCR between January 2013 and 
December 2015, and who received systemic posaconazole for the prophylaxis against IFI, 
were included into this retrospective analysis. Table 4.1 provides a brief breakdown of 
numbers of included patients as per the type of diagnosis of hematological malignancies.  
 
 
Table 4. 1. Types of hematological malignancies in patients included in the analysis 
Hematological malignancies n (%) 
Acute myeloid leukemia (AML) 45 (64.29) 
Precursor T/B-cell lymphoblastic leukemia/lymphoma 
(ALL) 
22 (31.43) 
Adult T-cell leukemia/lymphoma (ATLL) 1 (1.43) 
Myelosclerosis with myeloid metaplasia (MMM) 1 (1.43) 
Myelodysplastic syndrome (MDS) 1 (1.43) 
Total 70 (100) 
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4.1.1.2. Clinical Outcomes  
Out of 70 patients, who received systemic posaconazole for prophylaxis against IFI 
in the retrospective analysis, 30 (42.86%) had failed their therapy due to IFI. The majority 
of those patients were diagnosed with AML (n=22) while the rest had ALL (n=7) and 
ATLL (n=1) patients. Only 5 patients had died before completing the follow-up 112 days 
(4 patients with AML and 1 with ALL), which is a crude mortality rate of 7.14%. The mean 
age of included patients was 39.97 ± 15.15 (ranging from 16 to 70), with the majority 
(n=58, 82.86%) of the study patient population being males. The mean number of days of 
receiving posaconazole among patients, where therapy was successful (no IFI or death 
within 112 days), was 63.1 days. The patients who failed therapy due to developing IFIs 
had a mean posaconazole duration of 56.3 days, and those who failed therapy due to death 
had a mean therapy duration of 25.4 days. In Table 4.2, probability estimates of success, 
failure due to IFI, IFI-causative fungi, ADR with success, and death are provided. Death 
medical reports did not clarify or investigate the reason of death; therefore, no information 
on IFI-specific mortality is available.  
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Table 4.2. Model input probabilities of ADR and IFI-causative fungi 
Study clinical outcome Probability with 
posaconazole 
Resource 
Therapy success 0.50 NCCCR medical records 
      With major ADR 0.13 Ullmann et al.103 
       With minor ADR 0.15 
      Without ADR 0.72 
Therapy failure due to IFI 0.43 NCCCR medical records 
      Aspergillus 0.30 NCCCR expert panel 
      Candida 0.60 
      Fusarium  0.03 
      Mucormycetes 0.03 
      Tricosporon  0.03 
Death 0.07 NCCCR medical records 
 
 
Patients received routine screening procedures and monitoring tests during 
prophylaxis among all hematological malignancy patients in NCCCR during the study 
duration (Table 4.3). 
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Table 4. 3.Utilization of screening procedures and monitoring tests in patients 
Screening tests 
(imaging)  
No. of 
tests 
conducted  
Test 
frequency 
Screening tests 
(pathology)  
No. of 
tests 
conducted  
Test 
frequency 
Chest X-ray  652 Weekly Respiratory culture  46 Weekly  
Other X-ray  51 As needed  Parasite stool 15 Biweekly 
CT scan1 143 Weekly Acid-fast bacilli  38 Biweekly  
Ultrasound  40 Weekly  C. Diff toxin4 55 As 
needed 
MRI2 37 Weekly C. Coli antigen5 22 As 
needed  
Nuclear 
Medicine 
30 As needed Galactomannan test 324 As 
needed  
ECG3 64 Weekly  PCR virology6 65 As 
needed 
Screening tests (Pathology)  Monitoring tests  
Urine culture  219 Weekly ALT/AST7 3,454 Twice 
weekly 
Stool culture 48 Weekly Creatinine  5,178 Weekly 
Blood culture  771 Weekly CBC8 5,302 Weekly  
1 CT: Computed Tomography                      5 C. Coli: Campylobacter Coli 
2 MRI: Magnetic Resonance Imaging             6 PCR: Polymerase Chain Reaction 
3 ECG: Electrocardiogram                             7 ALT/AST: Alanine Transaminase/Aspartate 
Transaminase 
4 C. Diff: Clostridium Difficile                        8 CBC: Complete Blood Count 
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Based on the expert panel, the management of minor ADR, as deemed relevant to 
posaconazole, were as in Table 4.4. Also, as per the expert panel, the alternative antifungal 
therapies given after the discontinuation due to major ADR or the failure of prophylaxis 
are as in Tables 4.5 and 4.6.  
 
Table 4. 4. Management of minor ADR during posaconazole administration 
Type of ADR Management medication Details (dose, frequency, duration) 
Headache Paracetamol 1000 mg every 6 hours for 10 days as 
needed 
Nausea and vomiting Metoclopramide 10 mg twice daily for 2 weeks as needed 
Diarrhea Metronidazole 500 mg every 8 hours for 10 days 
 
 
Table 4. 5. Antifungal alternative medication in case of discontinuation due to major 
ADR 
Cause of therapy 
discontinuationa 
Management 
medication  
Details (dose, frequency, 
duration) 
Sever liver and biliary disorder  LAMB  5 mg/kg/day for 12 weeks  
a Patients stop prophylaxis in this case and start the alternative therapy for treatment 
purpose once evidence of infection appears 
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Table 4. 6. Antifungal alternative medications to therapy failure due to the 
occurrence of IFI 
Causative 
pathogen 
Alternative treatment Details (dose, frequency, duration) 
Aspergillus  Voriconazole  Loading dose 6 mg/kg twice daily for day 1, 
followed by maintenance IV dose 4 mg/kg 
twice daily for 2 weeks, then oral 200 mg 
twice daily for 10 weeks  
Candida  Caspofungin   Loading dose 70 mg once daily for day 1 
followed by 50 mg once daily for 6 weeks 
Fusarium    LAMB + Voriconazole   Voriconazole: Loading dose 6 mg/kg twice 
daily for day 1, followed by maintenance IV 
dose 4 mg/kg twice daily for 2 weeks, then 
oral 200 mg twice daily for 10 weeks + 
LAMB: 5 mg/kg/day for 12 weeks 
Mucormycetes LAMB+ surgical 
debridement 
5 mg/kg/day for 6 weeks  
Tricpsporon Voriconazole Loading dose 6 mg/kg twice daily for day 1, 
followed by maintenance IV dose 4 mg/kg 
twice daily for 2 weeks, then oral 200 mg 
twice daily for 10 weeks 
 
 
4.1.1.3. Economic Outcomes  
The cost inputs of resources included in the model are summarized in Table 4.7. 
Based on the study model, as illustrated in Chapter 3, the average overall cost of 
posaconazole was QAR 109,802 per patient. The cost of the success of therapy was QAR 
52,029 per patient, the total cost due to IFI-based failures was QAR 54,948 per patient, and 
the cost associated with the death pathway was QAR 2,824 per patient. Table 4.8 
summarizes the calculation of the overall cost of posaconazole therapy. 
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Table 4. 7. Resource costs 
Item Unit Unit cost (QR) 
Posaconazole 105 mL oral suspension 3295.56 
Voriconazole 200 mg IV vial 364.18 
200 mg oral tablet 148.89 
Caspofungin 50 mg IV vial 1203.96 
70 mg IV vial 1573.14 
LAMB 50 mg IV vial w/microfilter 655.47 
Paracetamol  500 mg oral tablet 0.03 
Metronidazole  500 mg oral tablet 0.07 
Metoclopramide  10 mg oral tablet 0.05 
Chest X-ray 1 test 36 
CT scan 1 test 486 
Ultrasound scan 1 test 84 
MRI scan 1 test 876 
Nuclear medicine  1 test 1,000 
ECG 1 test 600 
Sputum culture ≥1 tests (1 culture) 92 
Urine culture  1 test (1 culture) 92 
Stool culture  ≥ 1 tests (1 culture) 92 
Blood culture 1 test (1 culture) 92 
Respiratory culture  1 test 92 
Parasite stool 1 test 92 
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       All costs are based on pricing system of NCCCR 
 
 
 
 
Acid-fast bacilli 1 test 92 
Clostridium 
Difficle toxin 
1 test 200 
Campylobacter  Coli antigen  1 test  200 
Skin biopsy  1 test 123 
PCR virology  1 test 200 
Surgical debridement  1 procedure  1,000 
Galactomannan (ELISA) 1 test 66 
Co-agulation test 1 test 42 
Fibrinogen  1 test 28 
C-reactive protein 1 test 24 
Complete blood count 1 test 30 
Renal function test 1 test 90 
Liver function test 1 test 30 
Hospitalization Inpatient per day 100 
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Table 4. 8. Cost consequences of utilizing posaconazole at NCCCR as per the study 
model 
Antifungal 
agent 
Outcome Event 
Cost of 
pathway x 
probability 
(QARa) 
Arm cost 
(QAR) 
Average Cost 
 (QAR, 95% CIc) 
Posaconazole Success with major ADRb 29,705 52,029 109,801  
(109,750 - 109,852) Success with minor ADR 3,922 
Success without ADR 18,402 
Failure due to Aspergillus   13,293 54,948 
Failure due to Candida 29,311 
Failure due to Fusarium  7,153 
Failure due to 
Mycormycosis 
3,715 
Failure due to Tricosporon 1,477 
Death  2,824 2,824 
a QAR: Qatari Riyal                                                            
b ADR: Adverse Drug Reaction 
c CI: Confidence Interval, Based on 10,000 iterations of multivariate Monte Carlo simulations 
 
 
The costs as per the different patient management components are illustrated in 
Figure 4.1, where it is shown that the main cost driver was success with the major ADR 
pathway (30% of total expenditure), followed by the average cost of monitoring tests 
(19%), and Candida-based failure pathways (17.5%), and then the acquisition cost of 
posaconazole (15%). Prices and estimated monthly costs antifungal agents are shown in 
Table 4.9. 
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Figure 4. 1. Cost of management breakdown of patients on posaconazole 
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Table 4. 9. Systemic antifungal agents utilized in the model with their costs 
Antifungal agent DDD (mg)a Mean DDD per 
month (mg) 
Mean cost per month 
(QAR) 
Posaconazole 600 18,000 16,47 
Voriconazole (IV)b 568 17,040 31,028 
Voriconazole (PO)c 400 12,000 8,933 
Caspofungin 50 1,500 36,119 
LAMB 355 10,650 139,615 
a DDD: defined daily dose (based on patient’s average weight at NCCCR), b IV: 
intravenous, c PO: oral 
 
 
 
As illustrated in Figure 4.2, while the death outcome was associated with the lowest 
monitoring cost (QAR 19,774), the monitoring in cases of Aspergillus, Fusarium, and 
Tricosporon infections, and as anticipated, necessitated higher consumption of resources 
and was, hence, associated with higher cost (QAR 37,590). 
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Figure 4. 2. Cost of monitoring based on the outcome 
 
 
 
According to the data collected from NCCCR records, the cost of all tests and 
procedures that were conducted for all included patients throughout the whole following 
up period (112 days) reached QAR 1,082,066. Table 4.10 provides the cost contribution of 
each test in the overall cost.  
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Table 4.10. Breakdown of cost contribution of each monitoring and diagnostic tests 
in the overall cost 
Test /procedure Cost (QAR) Contribution (%) 
X-rays  25,308  2.3 
CT-scan  69,498 6.4 
Ultrasound 3,360 0.3 
MRI 32,412 3 
Nuclear medicine 30,000 2.8 
ECG 38,400 3.5 
Urine culture 20,148 1.9 
Stool culture  4,416 0.4 
Blood culture 70,932 6.6 
Respiratory culture 4,232 0.4 
Parasite stool 1,380 0.1 
Acid fast-bacilli 3,496 0.3 
Clostridium Difficile toxin 11,000 1 
Campylobacter Coli antigen 4,400 0.4 
Galactomannan test 21,384 2 
PCR virology  13,000 1.2 
ALT/AST 103,620 9.6 
Creatinine  466,020 43.1 
CBC 159,060 14.7 
Total costs 1,082,066 100 
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4.1.1.4. Sensitivity Analysis  
One-way Sensitivity Analysis  
Table 4.11 Shows the uncertainty range of input variables used in one-way sensitivity 
analyses.  
 
Table 4.11. Uncertainty range for variables in sensitivity analysis 
Variable 
Uncertainty range 
Low Base case High 
Posaconazole cost/bottle QR2,636.45 QR3,295.56 QR3,964.67 
Voriconazole cost/vial (IV) QR291.34 QR364.18 QR437.02 
Voriconazole cost/tablet (PO) QR119.11 QR148.89 QR178.67 
Caspofungin cost/vial (50 mg) QR963.18 QR1,203.97 QR1,444.76 
Caspofungin cost/vial (70 mg) QR1,258.51 QR1,573.14 QR1,887.77 
LAMB cost/vial QR522.38 QR655.47 QR788.56 
Hospitalization cost/day QR0 QR100 QR200 
Accounting for the costs of 
diagnostic tests 
No Yes 
 
- 
Accounting for major ADR 
occurrence  
No Yes 
- 
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Not including major ADR into the analysis, only limiting ADR to minor, led to a 
reduction of QAR 26,370 in the cost per patient (QAR 109,802 vs. 83,432). Eliminating 
the cost of hospitalization just reduced the total cost of therapy by 2.7% (QAR 109,802 vs. 
106,796), and the cost of the major ADR and failure due to IFIs pathways by QAR 546 and 
QAR 2,460, respectively. Not accounting for costs of diagnostic procedures produced 
14.6% reduction in the total posaconazole cost to QAR 93,816 per patient.  The outcome 
of ±20% variation in drug prices is as illustrated in Table 4.12. Figures 4.3 - 4.8 illustrate 
the probability cost-of-therapy curves with variations in drug prices. The cost-of-therapy 
curve demonstrate the probability of different potential cost values to take place. It is a 
reflection of the distribution between varied input values within an uncertainty range and 
the resulting outcome to each.  
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Table 4.12. Sensitivity to variability in drug prices 
Antifungal 
Medication 
Min 
price 
(QAR)a 
Base case 
price 
(QAR) 
Max 
price 
(QAR) 
Min total 
cost 
(QAR) 
Mean 
total cost 
(QAR) 
Max total 
cost  
(QAR)  
Posaconazole 2,636 3,295 3,954 108,122 113,486 118,849 
Voriconazole 
(IV)b 
292 364 437 113,006 113,457 113,900 
Voriconazole 
(PO)c 
119 149 178 112,806 113,455 114,098 
Caspofungin 
70 mg 
1260 1573 1884 113,376 113,456 113,536 
Caspofungin 
50 mg 
965 1,203 1,442 110,938 113,451 115,967 
LAMB 535 666 796 107,279 113,463 119,650 
a QAR: Qatari Riyal                    b IV: intravenous                          c PO: oral 
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Figure 4.3. Cost-of-therapy probability curve with posaconazole price change 
Figure 4.4. Cost-of-therapy probability curve with voriconazole (IV) price change 
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Figure 4.5. Cost-of-therapy probability curve with voriconazole (PO) price change 
Figure 4.6. Cost-of-therapy probability curve with caspofungin (70 mg vial) price change 
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Figure 4.7. Cost-of-therapy probability curve with caspofungin (50 mg vial) price 
changes 
Figure 4.8. Cost-of-therapy probability curve with LAMB price changes 
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Multivariate Probabilistic Sensitivity Analysis  
Table 4.13. Input variables and uncertainty distributions used in multivariate 
analysis 
Input variables  Uncertainty distribution  
posaconazole 
Success Triangular distribution, 0.485,0.5,0.515 
    With major ADR Triangular distribution, 0.1261,0.13,0.1339 
     With minor ADR Triangular distribution, 0.1482,0.15282,0.1574 
     Without any ADR Triangular distribution, (0.6957,0.71717,0.7387 
Therapy failure  Triangular distribution, 0.416,0.42857142,0.441 
    Due to Aspergillus  Triangular distribution, 0.285,0.3,0.315  
     Due to Candida Triangular distribution, 0.57,0.6,0.63 
      Due to Fusarium Triangular distribution, 0.03166,0.03333,0.03499 
Due to  Muocormycosis  Triangular distribution, 0.03166,0.03333,0.03499 
      Due to Tricosporon  Triangular distribution, 0.03166,0.03333,0.03499 
Death Triangular distribution, 0.0679,0.0714285,0.0721 
 
 
Figure 4.9 shows the probability cost-of-therapy curve with posaconazole in the 
multivariate analysis. In the tornado analysis shown in Figure 4.10, the model pathways 
are ranked as per their influence on the study outcome; whereby the success has the highest 
impact on the therapy cost, and failure due Fusarium infection has the least impact on the 
outcome. 
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Figure 4.9. Cost-of-therapy probability curve with posaconazole in multivariate analysis 
Mean 
12,220 
Figure 4. 10. Tornado diagram showing the influence of model outcomes on the average 
posaconazole overall cost 
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Scenario Sensitivity Analysis  
The analysis of the scenario of sharing the posaconazole bottle among different 
patients led to a minor reduction in the total average cost of posaconazole, by only QAR 
908 per patient.  
4.1.2. Evaluation 2: Cost-Effectiveness Analysis of the Comparative Economic Value 
of Posaconazole Against Fluconazole 
4.1.2.1. Study Model and Patients  
As indicated in Chapter 3, the current study’s economic model, with the structure 
of which also described in Chapter 3, is based on the multicenter, double-blind and double-
dummy, multinational clinical trial by Ullmann et al103, which was adopted to the local 
setting via an expert panel and the medical records. Included patients in the trial were above 
12 years old and weighed over 34 kg, who had undergone HSCT and had either acute 
GVHD or chronic GVHD. Patients were excluded if they had a history of proven or 
probable fungal infections, or if IFI was suspected at baseline, had hepatic dysfunction that 
is clinically significant as indicated by elevated levels of alanine aminotransferase or 
aspartate aminotransferase (10 times higher than the normal upper limit), had renal 
dysfunction, or had taken medications known to interact with azoles.  
The study assigned 301 eligible patients to receive posaconazole and 299 patients 
to receive fluconazole for the prophylaxis against IFI. Patient baseline characteristics and 
demographic data were similar and comparable between both arms103. 
4.1.2.2. Data Provided by Expert panel  
On the basis of the median and range durations provided by Ullmann et al.103, the 
duration of therapy was estimated to be 80 days with posaconazole and 77 days with 
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fluconazole. For both prophylactic options, patient monitoring comprised a daily complete 
blood count (CBC) and renal function tests, while liver function tests were collected twice 
weekly. As for diagnostic tests, chest X-ray, galactomannan by ELISA, fibrinogen test and 
C-reactive protein (CRP) were performed on a weekly basis. All patients received a CT 
scan at least once upon physician request. Blood, urine, sputum, and stool microbiological 
cultures were performed at least once a week. The 40 patients with major ADR, reported 
in 107 patients on posaconazole with ADR, had severe hepatotoxicity that necessitates 
therapy discontinuation. As for the fluconazole arm, severe hepatotoxicity occurred in 29 
patients, and the remaining 86 patients (out of 115 patients with ADR) had minor ADR. 
Out of all 43 IFIs that were detected in the study, aspergillosis occurred in 7 patients 
receiving posaconazole and 21 patients in the fluconazole arm. Candida and Fusarium 
infections occurred in the remaining 15 patients (4 patients with each study drug were 
infected with Candida, while 5 in the posaconazole arm got Fusarium infection versus 2 
in the fluconazole arm). Medications recommended by the expert panel for the 
management of minor ADR, which were irrelevant to the study drugs, are clarified in Table 
4.14. As per the expert panel, patients with major ADR in NCCCR would have their 
prophylactic therapy withhold to avoid further harm and will be starting an antifungal 
treatment once signs of IFI appear, with the choice of therapy being LAMB. This, together 
with the alternative antifungal therapies to the failure of prophylaxis, are as in Tables 4.15 
and 4.16. 
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Table 4.14. Management medications of minor ADR due to posaconazole and 
fluconazole 
Type of ADRa Management 
medication  
Details (dose, frequency, 
duration) 
Headache  Paracetamol  1000 mg every 6 hours for 10 
days as needed 
Nausea and 
vomiting  
Metoclopramide  10 mg twice daily for 2 weeks as 
needed 
Diarrhea   Metronidazole  500 mg every 8 hours for 10 days 
a Minor liver and biliary disorders receive no interventions as per NCCCR 
practices, where the patient will only be under observation 
 
 
 
Table 4. 15. Antifungal discontinuation alternatives due to major ADR, regardless 
of study drug 
 
 
Cause of therapy 
discontinuationa 
Management 
medication  
Details (dose, frequency, 
duration) 
Severe liver and biliary 
disorder  
LAMB  5 mg/kg/day for 12 
weeks 
a As per expert panel, other major ADR in the trial were not reported in 
NCCCR and hence will not be of study interest 
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Table 4. 16. Antifungal alternatives to therapy failure due to IFIs 
Causative 
pathogen a 
Alternative medicationb  Details (dose, frequency, duration) 
Aspergillus  Voriconazole  Loading dose 6 mg/kg twice daily for 
day 1, followed by maintenance IV 
dose 4 mg/kg twice daily for 2 weeks, 
then oral 200 mg twice daily for 10 
weeks   
Candida  Caspofungin   Loading dose 70 mg once daily for day 
1 followed by 50 mg once daily for 6 
weeks 
Fusarium    LAMB + Voriconazole   Voriconazole: Loading dose 6 mg/kg 
twice daily for day 1, followed by 
maintenance IV dose 4 mg/kg twice 
daily for 2 weeks, then oral 200 mg 
twice daily for 10 weeks + LAMB: 5 
mg/kg/day for 12 weeks 
a Minor liver and biliary disorders had no intervention as per NCCCR practice as 
the patient will be under supervision 
b The alternative medication is the same for both arms (posaconazole and 
fluconazole)  
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4.1.2.3. Model Outcome Probabilities  
For each of the posaconazole and fluconazole therapies, outcome probabilities and the 
duration of therapy in the different patient states were calculated as follow:  
 Posaconazole Arm  
- In 301 patients in the posaconazole arm of the Ullmann et al. study the number of 
deaths in the exposure period = 22, and the number of patients who got IFIs = 16; 
hence, number of patients in the success arm is: 301 - 22 - 16 = 263, and the 
probabilities of occurrence of each outcome and consequences are as follow: 
• Therapy success: 263/301 = 0.87. 
• Therapy failure due to IFI: 16/301 = 0.05. 
• Therapy failure due to death: 22/301 = 0.07. 
• Major ADR events: 40/301 = 0.133. 40 major ADR were reported with 
posaconazole in the trial. 
• Minor ADR, headache: 3/301 = 0.01. 
• Minor ADR, diarrhea: 8/301 = 0.03. 
• Minor ADR, nausea and vomiting: 35/301 = 0.12. 
• Total minor ADR: 46/301 = 15.3. 
• No any ADR events: 1 - (0.133 + 0.153) = 0.714, which adds to 215 patients.  
• Probabilities of causative pathogen: Aspergillus = 7/16 = 0.44, Candida = 
4/16 = 0.25, Fusarium = 5/16 = 0.31. 
• If the mean number of days of therapy until failure due to IFI event = 102, 
percentage of patients who had IFIs = 5.3%, the mean number of days of 
therapy for all outcomes (success, failure, and death) = 80, and percentage 
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of patients who had therapy success or death = 100% - 5.3% = 94.7%, then 
the mean number of days of therapy with patients who had therapy success 
or death (i.e. X) is: (102 * 0.053) + (X * 0.947) = 80, and so X = 78.8 days 
of therapy. 
 Fluconazole Arm 
- In 299 patients in the fluconazole arm of the Ullmann et al. study the number of 
deaths in the exposure period =24 and the number of patients who got IFIs = 27; 
hence, the number of patients in the success arm is:  299 – 24 - 27 = 248, and the 
probabilities of occurrence of each outcome and consequences are as follow: 
• Therapy success: 248/299 = 0.83. 
• Therapy failure due to IFI: 27/299 = 0.09. 
• Therapy failure due to death: 24/299 = 0.08. 
• Major ADR events: 29/299 =0.0969. 29 major ADR were reported with 
fluconazole in the trial. 
• Minor ADR, headache: 8/299 = 0.3. 
• Minor ADR, diarrhea: 12/299 = 0.4. 
• Minor ADR, nausea and vomiting: 43/299 = 0.14. 
• Total minor ADR: 63/299 = 0.211. 
• No any ADR events: 1 - 0.0969 + 0.2107 = 0.692, which is 207 patients. 
• Probabilities of causative pathogen: Aspergillus = 21/27 = 0.778, Candida 
= 4/27 =0.148, Fusarium = 2/27 = 0.074. 
• If the mean number of days of therapy until failure due to IFIs = 88, 
percentage of patients who had IFI = 9%, mean number of days of therapy 
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for all outcomes (success, failure, and death) = 77, and percentage of 
patients who had therapy success or death = 100% - 9% = 91%, then the 
mean number of days of therapy with patie 
nts who had therapy success or death (i.e. X) is: (88 * 0.09) + (X * 0.91) = 
77, and so X = 75.9 days of therapy. 
The clinical outcomes and their probabilities are summarized in Table 4.17.   
 
 
Table 4. 17. Outcomes and probabilities of posaconazole and fluconazole103 used in 
the model 
Study clinical 
outcome 
Probability with 
posaconazole, % (n=301) 
Probability with 
fluconazole, % (n=299) 
Therapy successa 87.4 (263) 83.0 (248) 
     With major ADR 13.3 (40) 9.70 (29) 
     With minor ADR 15.3 (46) 21.1 (63) 
     Without ADR 71.4 (215) 69.2 (207) 
Therapy failure due 
to IFI 
5.30 (16) 9.00 (27) 
      Aspergillus  44 .0 (7) 77.8 (21) 
      Candida 25.0  (4) 14.8 (4) 
      Fusarium  31.0 (5) 7.40 (2) 
Death  7.30 (22) 8.00 (24) 
a All ADR are only considered in the success arm 
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4.1.2.4. Economic Outcomes  
Table 4.18. Summarizes all cost inputs used in the current model. 
 
Table 4.18. Recourse costs 
Item Unit Unit cost (QR) 
Posaconazole 105 mL oral suspension 3295.56 
Fluconazole 50 mg oral capsule 6.83 
Voriconazole 200 mg IV vial 364.18 
200 mg oral tablet 148.89 
Caspofungin 50 mg IV vial 1203.97 
70 mg IV vial 1573.14 
LAMB 50 mg IV vial w/microfilter 655.47 
Paracetamol  500 mg oral tablet 0.03 
Metronidazole  500 mg oral tablet 0.07 
Metoclopramide  10 mg oral tablet 0.05 
Chest X-ray 1 test 36 
CT scan 1 test 486 
Ultrasound scan 1 test 84 
MRI scan 1 test 876 
Sputum culture ≥1 tests (1 culture) 92 
Urine culture  1 test (1 culture) 92 
Stool culture  ≥ 1 tests (1 culture) 92 
Blood culture 1 test (1 culture) 92 
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Skin biopsy  1 test 123 
Galactomannan (ELISA) 1 test 66 
Co-agulation test 1 test 42 
Fibrinogen  1 test 28 
CRP 1 test 24 
Complete blood count 1 test 30 
Renal function test 1 test 90 
Liver function test 1 test 30 
Hospitalization Inpatient per day 100 
All costs are based on pricing system of NCCCR 
 
 
Based on success definition of the current project (success with no major ADR), 
posaconazole and fluconazole were of similar effectiveness to prevent IFIs (0.76 vs. 0.75). 
As reported by Ullmann et al, posaconazole was associated with a slightly lower rate of 
IFIs than fluconazole (0.05 vs. 0.09, odds ratio, 0.56; 95% CI, 0.30–1.07; p = 0.07). 
Prophylaxis with fluconazole was associated with a rate of success with minor ADR of 
0.17 compared to 0.13 with the posaconazole prophylaxis. On the other hand, for success 
rate with major ADR, the rate was lower in the fluconazole recipients than those taking 
posaconazole (0.08 vs. 0.11). While failure due to Fusarium infection was of a slightly 
lower rate with fluconazole than with posaconazole (0.01 vs. 0.02), the rate of the 
Aspergillus infection was higher in the fluconazole arm (0.07 vs. 0.02). The overall therapy 
cost of each of posaconazole and fluconazole is as in Table 4.19.  
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The estimated total average costs (including managing side effects, drug 
discontinuation, monitoring, and treatment in case of prophylaxis failure) were QAR 
80,463 per patient in the fluconazole arm and QAR 134,116 per patient in the posaconazole 
arm, with a mean difference of QAR 53,653 in favor of fluconazole. Posaconazole was 
also associated with a higher overall cost of success (QAR 114,145 versus QAR 66,243), 
and a higher total cost of managing IFIs (QAR 14,221 versus QAR 11,018), respectively. 
The cost of treating major ADR was QAR 17,877 higher with posaconazole.  
 80 
 
Table 4. 19. Clinical outcomes, probabilities and costs of consequences as per the study model 
Alternative Outcome Event Probability Cost (QAR) Average Cost (QAR, 95% CIa) 
Posaconazole Success with major ADR 0.11 54,339 134,116 (133,915-134,317) 
 
Success with minor ADR 0.13 10,506 
 
Success without ADR 0.63 49,300 
 
Failure due to aspergillosis infection  0.02 3,321 
 
Failure due to candida infection  0.01 2,028 
 
Failure due to Fusarium infection  0.02 8,872 
 
Death  0.07 5,750 
Fluconazole  Success with major ADR  0.08 36,462 80,463 (80,342-80,584) 
 
Success with minor ADR 0.17 6,973 
 
Success without ADR 0.57 22,808 
 
Failure due to aspergillosis infection  0.07 6,432 
 
Failure due to candida infection  0.01 1,356 
 
Failure due to Fusarium infection  0.01 3,230 
 
Death  0.08 3,202 
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For the purpose of the cost-effectiveness analysis, the ‘success’ outcome of interest 
in the simulation model was the success with no major ADR within 112 days of receiving 
the prophylactic therapy. Hence, the probability of therapy success with posaconazole is: 
0.13 + 0.63 = 0.76, while this is: 0.174 + 0.571 = 0.75 with fluconazole. Taking this and 
the higher cost of posaconazole in consideration, a Decremental Cost-Effectiveness Ratio 
(DCER) of fluconazole over posaconazole for each lost case of success was calculated as 
follows:  
𝐷𝐶𝐸𝑅 =  
𝐶𝑜𝑠𝑡 𝑜𝑓 𝑝𝑜𝑠𝑎𝑐𝑜𝑛𝑎𝑧𝑜𝑙𝑒−𝐶𝑜𝑠𝑡 𝑜𝑓 𝑓𝑙𝑢𝑐𝑜𝑛𝑎𝑧𝑜𝑙𝑒
𝐸𝑓𝑓𝑒𝑐𝑡 𝑜𝑓 𝑝𝑜𝑠𝑎𝑐𝑜𝑛𝑎𝑧𝑜𝑙𝑒−𝐸𝑓𝑓𝑒𝑐𝑡 𝑜𝑓 𝑓𝑙𝑢𝑐𝑜𝑛𝑎𝑧𝑜𝑙𝑒 
  = 
134,116.25−80,463.38
0.76−0.75 
 = QAR  
3,922,618 to be saved with fluconazole for each lost case of success 
 
Figure 4.11 illustrates the cost components and their proportional contribution to the total 
costs of fluconazole and posaconazole therapies. 
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Figure 4.11 Breakdown of cost components for both antifungal alternatives 
 
 
As for hospitalization and its cost, patients at the NCCCR receive prophylaxis 
therapy through visiting the outpatient clinic, where no need for hospitalization is 
indicated. Cost of hospitalization was only considered in two situations; when patients get 
IFI and, hence, require treatment therapy and/or when a major liver and biliary ADR 
occurs, seeing that patients would discontinue the prophylaxis therapy and will need to be 
under close monitoring. Interestingly, the cost of hospitalization with posaconazole was 
slightly lower than that associated with fluconazole (QAR 8,442 versus QAR 8,610, per 
patient).  
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4.1.2.5. Sensitivity Analysis 
One-way Sensitivity Analysis  
Key variables, the ranges over which they were varied, and their outcomes are as 
in Table 4.20. Important is that the study outcomes were not sensitive to any uncertainty 
that was associated with any of the model’s key inputs. 
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Table 4.20. Variation range for variables used in one-way sensitivity analyses with their cost-effectiveness outcome 
Variable 
Variation range Average 
posaconazole 
cost (QAR) 
Average 
fluconazole 
cost (QAR) 
DCER of lost success (QAR)a 
Low Base case High 
Posaconazole 
cost/bottle 
QR2,636.45 QR3,295.56 QR3,964.67 
142,810 vs. 
126,782 
91,239 3,770,438 vs. 2,598,548 
Fluconazole 
cost/tablet 
QR43.76 QR54.70 QR65.46 134,796 
92,297 vs. 
90,182 
3,107,174 vs. 3,261,812 
Voriconazole 
cost/vial 
QR291.34 QR364.18187 QR437.02 
135,091 vs. 
133,823 
91,807 vs. 
90,176 
3,164,480 vs. 3,191,130 
Voriconazole 
cost/tablet 
QR119.11 QR148.89377 QR178.67 
Caspofungin 
cost/vial (50 mg) 
QR963.18 QR1,203.96581 QR1,444.76 
134,253 vs. 
133,983 
90,880vs. 
90,608 
3,171,051 vs. 3,171,184 
Caspofungin 
cost/vial (70mg) 
QR1,258.51 QR1,573.13721 QR1,887.77 
LAMB cost/vial QR522.38 QR655.47 QR788.56 
144,463 vs. 
123,773 
97,866 vs. 
83,622 
3,406,780 vs. 2,935,454 
Hospitalization 
cost/day 
QR0 QR100 QR200 
136,141 vs. 
133,451  
92,638 vs. 
89,840 
3,180,528 vs. 3,188,456 
Duration of therapy 
in posaconazole 
- 
78.8 days for 
success and 
death pathway 
102 days for 
failure pathway 
53 days for 
success and 
death 
pathway 62 
days for 
failure 
pathwaya 
 
121,665  91,239 2,224,490 
a The estimated durations are based on the actual average duration of prophylaxis identified in e-medical records at NCCCR 
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Cont. Table 4.20. Variation range for variables used in one-way sensitivity analyses with their cost-effectiveness outcome 
Variable 
Variation range Average 
posaconazole cost 
(QAR) 
Average 
fluconazole cost 
(QAR) 
DCER of lost 
success (QAR)a Low Base case High 
Duration of therapy 
in fluconazole  
- 
75.9 days for 
success and 
death pathway 
88 days for 
failure pathway 
53 days for 
success and 
death 
pathway 62 
days for 
failure 
pathway 
134,796 77,569 4,183,922 
Fusarium 
probability in 
posaconazole arm  
0.25 (-20%) 0.31 - 132,285 80,463 3,788,735 
Fusarium 
probability in 
fluconazole arm 
0.06 (-20%) 0.07  134,116 79,675 3,980,239 
Major ADR in 
posaconazole arm  
0.05 (-60%) 0.13  101,513 80,463 1,538,935 
Major ADR in 
fluconazole arm  
 0.10 0.2 (+100%) 134,116 116,926 1,256,807 
Counting for the 
costs of diagnostic 
tests 
No Yes 
 
- 
117,336 72,813 3,255,144 
a The estimated durations are based on the actual average duration of prophylaxis identified in e-medical records at NCCCR 
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Multivariate Probabilistic Sensitivity Analysis  
The input variables and their uncertainty distributions are shown in Table 4.21. 
Importantly, out of 10,000 simulations, the multivariate probabilistic sensitivity analysis 
of the economic model calculated that only in <5% of cases the DCER with posaconazole 
would be reduced to less than QAR 1,200,000 per success. The model outcome was robust 
in 95.6% of cases, with 4.4% chance for posaconazole to become dominant over 
fluconazole; higher rate of success without major ADR and lower overall cost.  
 
Table 4. 21. Input variables and uncertainty distributions used in Monte Carlo 
simulation 
Input variables  
Uncertainty distribution  
posaconazole fluconazole  
Success   
    With major ADR Triangular distribution, 
0.1067,0.11,0.1133  
Triangular distribution, 
0.0776,0.08,0.0824 
     With minor ADR Triangular distribution, 
0.1261,0.13,0.1339 
Triangular distribution, 
0.1649,0.17,0.1751  
     Without any ADR Triangular distribution, 
0.6111,0.63,0.6489 
Triangular distribution, 
0.5548,0.572,0.589  
Therapy failure    
    Due to Aspergillus  Triangular distribution, 
0.0194,0.02,0.0226  
Triangular distribution, 
0.0679,0.07,0.0721  
     Due to Candida Triangular distribution, 
0.0097,0.01,0.0103 
Triangular distribution, 
0.0097,0.01,0.0103  
      Due to Fusarium Triangular distribution, 
0.0194,0.02,0.0206  
Triangular distribution, 
0.0097,0.01,0.0103 
Death Triangular distribution, 
0.0679,0.07,0.0721 
Triangular distribution, 
0.0776,0.08,0.0824  
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The tornado diagram in Figure 4.12 shows the rank of different study outcomes as 
per their influence on the study outcome, with the top influencing outcome being the 
success without ADR, and the least outcome of impact being the failure due to Candida 
infections.  
 
 
 
 
 
 
Mean 
15,327 
Figure 4. 12. Tornado diagram of all variables with their extent of influence on cost 
using the Monte Carlo simulation 
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Scenario Sensitivity Analysis  
The model was insensitive to the scenario of sharing the posaconazole bottles 
among patients, unlike the practice in NCCCR, Qatar. The DCER of fluconazole changed 
to QAR 2,996,157 saved per lost case of success.  
4.2. Phase 2: Systematic Review of Methodological Trends and Gaps, and the 
Reporting Quality of Comparative Economic Evaluations on the Use of Systemic 
Antifungal Agents Used for Prophylaxis Against IFI 
4.2.1. Inclusion and Study Description 
Out of 841 articles attained from the systematic search of the literature, only 19 
articles were eligible for inclusion in the study analysis (Figure 4.13). Table 4.22 provides 
a brief description of the included studies. The years the studies were conducted between 
2008 and 2013, except for one that was published earlier in 1997. Seven studies were 
conducted in the United States (USA)82,86,87,102105,106,107, whereas the remaining studies 
reported data from Australia90,91 , Canada108, Spain109,110,111, The Netherland81,85, Korea83, 
Greece112, France113, Germany111, and Switzerland88, with 1 to 2 studies in each. 
 
 
 
 
 
 
 89 
 
 
 
 
 
 
 
 
 
 
Figure 4. 13. Flowchart of literature search and inclusion 
 90 
 
Table 4. 22.Characteristics and main results of included economic articles   
R
eco
rd
 
N
o
. 
Last 
author, 
year 
Country Economic 
analysis method 
Perspective, 
time horizon 
Source of 
clinical 
data  
Intervention Comparator Sensitivity 
analysis  
Main economic 
finding 
Neutropenia patients with AMLa,MDSb 
1 de Vries, 
200681 
Germany & 
Netherland 
Cost-effectiveness Hospital, less 
than 1 year 
Rinaldi114 
& 
Kanda137 
Itraconazole Fluconazole 
or placebo 
One-way Itraconazole 
dominated 
fluconazole 
/placebo 
2 Stam, 
200885 
Netherland  Cost-effectiveness Hospital,100 
days 
Cornely89 Posaconazole fluconazole 
or 
itraconazole 
One way 
and 
Scenario 
Posaconazole 
dominated 
fluconazole 
/itraconazole 
3 Collins, 
200886 
USA Cost-effectiveness Hospital,100 
days 
Cornely89 Posaconazole fluconazole 
or 
itraconazole 
One-way Posaconazole 
dominated 
fluconazole 
/itraconazole 
4 Dranitsaris, 
2011108 
Canada Cost-effectiveness Hospital, until 
no IFI or IFI 
happen with 
death or 
survival 
Cornely89 Posaconazole fluconazole 
or 
itraconazole 
One-way Posaconazole 
dominated 
fluconazole 
/itraconazole 
5 Papadopoul
os, 2013105 
USA Cost-effectiveness Payer,100 days Cornely89 Posaconazole fluconazole 
or 
itraconazole 
One-way & 
Multivariat
e 
Posaconazole 
dominated 
fluconazole 
/itraconazole 
a AML: Acute Myeloid Leukaemia                                                                         b MDS: Myelodysplastic Syndrome 
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Cont. Table 4.22. Characteristics and main results of included economic articles  
R
eco
rd
 
N
o
. 
Last author, 
year 
Country Economic 
analysis 
method 
Perspective, 
time horizon 
Source of 
clinical 
data  
Intervention Comparator Sensitivity 
analysis  
Main 
economic 
finding 
6 Athanasakis, 
2013132 
Greece Cost-
effectiveness 
Third party 
payer,100 days 
Cornely89 Posaconazole fluconazole 
or 
itraconazole 
Multiple 
way   
Requires ICER 
7 Grau, 
2012109 
Spain Cost-
effectiveness 
Hospital, until 
death of IFI 
(markov) 
Cornely89 
& 
Kantarjian1
15 
Posaconazole fluconazole 
or 
itraconazole 
One-way & 
multivariate  
Posaconazole 
dominated 
fluconazole 
/itraconazole 
8 Michallet, 
2011113 
France Cost-
effectiveness 
Hospital, until 
death of IFI or 
other cause of 
death (markov)  
Cornely89 Posaconazole fluconazole 
or 
itraconazole 
One-way & 
multivariate 
Posaconazole 
dominated 
fluconazole 
/itraconazole 
9 Greiner, 
201088 
Switzerland Cost-
effectiveness 
Hospital ,100 
days 
Wingard121 
& 
Kantarjian
115 
Posaconazole fluconazole 
or 
itraconazole 
One-way Posaconazole 
dominated 
fluconazole/itr
aconazole 
among 
neutropenic 
patients only 
10 O’Sullivan, 
200987 
USA Cost-
effectiveness 
Payer,100 days Cornely89 Posaconazole fluconazole 
or 
itraconazole 
One-way, & 
scenario 
Posaconazole 
dominated 
fluconazole 
/itraconazole 
a AML: Acute Myeloid Leukaemia                                                                         b MDS: Myelodysplastic Syndrome 
c  HSCT: Haematopoietic Stem Cell Transplant                                                 d AIDS: Acquired Immune Deficiency Syndrome  
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Cont. Table 4.22. Characteristics and main results of included economic articles  
R
eco
rd
 N
o
. 
Last author, 
year 
Country Economic 
analysis 
method 
Perspective
, time 
horizon 
Source 
of 
clinical 
data  
Intervention Comparator Sensitivity 
analysis  
Main economic 
finding 
11 O’Sullivan, 
2012102 
USA Cost-
effectiveness 
Payer,112 
days 
Ullmann
103 
Posaconazole Fluconazole One-way Posaconazole is 
in the range of 
accepted criteria 
for cost-
effectiveness  
12 Schonfeld, 
200882 
USA Cost-
effectiveness 
Hospital,4 
weeks  
Burik116 Micafungin Fluconazole One-way Micafungin 
dominated 
fluconazole 
13 Sohn, 
200983 
Korea Cost-
effectiveness 
Payer, one 
year 
Park117, 
Moerem
ans118, 
Burik116, 
Min119 
& 
Briggs
120 
Micafungin Fluconazole One-way Micafungin 
dominated 
fluconazole 
14 Mauskopf, 
2013106 
USA Cost-
effectiveness 
Hospital, 
one year 
Wingard
121 
Voriconazole Fluconazole  One-way  Voriconazole is 
not dominant 
a AML: Acute Myeloid Leukaemia                                                                         b MDS: Myelodysplastic Syndrome 
c  HSCT: Haematopoietic Stem Cell Transplant                                                 d AIDS: Acquired Immune Deficiency Syndrome  
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Cont. Table 4.22. Characteristics and main results of included economic articles  
R
eco
rd
 
N
o
. 
Last author, 
year 
Country Economic 
analysis 
method 
Perspective, 
time horizon 
Source of 
clinical 
data 
Intervention Comparator Sensitivity 
analysis 
Main 
economic 
finding 
HSCT 
15 Sánchez-
Ortega, 
2013101 
Spain Cost-
effectiveness 
Hospital,100 
days 
Sanchez-
Ortega101 
Posaconazole Itraconazole One-way Requires 
ICER 
16 de la Ca´mara, 
2009111 
Spain Cost-
effectiveness 
Hospital,112 
days 
Ullmann10
3 
Posaconazole Fluconazole One-way & 
multivariate 
Requires 
ICER 
AML 
17 Heng, 201391 Australia Cost-
effectiveness 
Hospital, not 
applicable 
Chart 
review 
Fluconazole Posaconazole 
or 
Voriconazole 
One-way, 
multivariate 
& scenario 
Requires 
ICER 
18 Al-Badriyeh, 
201090 
Australia Cost-
effectiveness 
Hospital, until 
therapeutic 
success or 
death 
Chart 
review 
Voriconazole Posaconazole One-way & 
scenario 
Posaconazol
e dominated 
voriconazole 
AIDS 
19 Scharfstein, 
1997107 
USA Cost-
effectiveness 
Third party 
payer, Until no 
more than 
0.1% of the 
original cohort 
is still alive 
(Markov) 
Powderly
122 
Fluconazole Placebo One-way & 
two-way 
Requires 
ICER 
a AML: Acute Myeloid Leukaemia                                                                         b MDS: Myelodysplastic Syndrome 
c  HSCT: Haematopoietic Stem Cell Transplant                                                 d AIDS: Acquired Immune Deficiency Syndrome  
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4.2.2. Study Population  
Of the 19 included studies, around three quarter of them (n=14) were conducted 
among neutropenic patients suffering from AML and MDS, two studies focused on AML 
patients only, two focused on HSCT, and one included AIDS patients (Table 4.22). Age of 
patients was >13 years old in ten studies, and the age in the remaining (n=9) was in the 
range of 30-55 years old.  
4.2.3. Study Comparators 
Comparators among studies were posaconazole, fluconazole, itraconazole, 
micafungin, voriconazole, and placebo. Posaconazole was the most frequently involved 
drug in evaluations, where it was evaluated 23 times; versus itraconazole in 9 studies, 
fluconazole in 11 studies, voriconazole in 2, and once against placebo. Besides 11 
evaluations against posaconazole, fluconazole was evaluated against itraconazole and 
micafungin twice each, and against voriconazole and placebo once each. Study drugs and 
comparators are as in Table 4.22 and Figure 4.14.  
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4.2.4. Method of Economic Evaluation 
  With regards to the design of the pharmacoeconomic evaluations, all 19 articles 
utilized cost-effectiveness methodology and, except in two of them, they included decision 
analytic modeling82,110. Table 4.23 shows a CEA grid that summarizes how cost and 
outcomes compare among studies, with a state of dominance in 12 studies, mostly in favor 
of posaconazole, requiring no ICERs to be calculated. As for the remaining 7 articles, only 
five required ICER measurement due to an alternative having both higher effect and 
cost107,110,111,112 or lower effect and cost91. As summarized in Table 4.24, 12 studies 
incorporated cost per life year gained as an economic measure, 7 used the cost per IFI 
Figure 4. 14. Study comparisons   
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avoided outcome, 2 used the cost per QALY outcome, and 6 included the cost saving per 
patient measure.  
 
 
Table 4.23. CEA grid summary of study outcomes 
 
 
 
 
 
 
 
 
 
Cost/Effect Higher Effect Same Effect Lower Effect 
Higher Cost 4a   
Same Cost    
Lower Cost 12 (9 for posaconazole) 2b 1c 
a Scharfstein et al, 1997107, Athanasakis et al, 2013112,  Sánchez-Ortega et al, 
2013110, and  de la Ca´mara et al, 2009111 
b O’Sullivan et al, 2012102 and Mauskopf et al, 2013106 
c Heng et al, 201391 
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Table 4.24. Outcome measures of economic evaluations 
Type of outcome 
measure 
Cost per life year 
gained  
Cost per IFI 
avoided 
QALY Cost saving per 
patient. 
Last authora Papadopoulos, 
2013 
O’Sullivan, 2009 
O’Sullivan, 2012 
Mauskopf, 2013 
Scharfstein, 1997 
Dranitsaris, 2011 
Grau, 2012 
Sánchez-Ortega, 
2013 
de la Ca´mara, 
2009 
Stam, 2008 
Athanasakis, 
2013 
Greiner, 2010 
O’Sullivan, 
2009 
O’Sullivan, 
2012 
Mauskopf, 2013 
Sánchez-Ortega, 
2013 
de Vries, 2006 
Athanasakis, 
2013 
Greiner, 2010 
 
 
Scharfstein, 
1997 
Stam, 2008 
 
Collins, 2008 
Schonfeld, 2008 
Heng, 2013 
Al-Badriyeh, 
2010 
Sohn, 2009 
Michallet, 2011 
 
a Different outcome measures can be reported under the same author as  some economic 
evaluations included more than one outcome measure 
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4.2.5. Clinical Inputs and Definitions 
Outcomes of interest were extensively variable among the different decision 
models. Figure 4.15 illustrates all the different clinical measures that were used in studies, 
noting that a study can include several comparative models. A summative decision tree that 
includes all decision analytic trees in the studies’ models is shown in Appendix 9.  
 
 
 
Figure 4.15. Different clinical outcome pathways used in study models  
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Important is that the way different researchers defined similar outcome measures 
in studies were different. For example, success was defined by Sohn et al83. as the absence 
of proven, probable, or suspected systemic fungal infection through the end of prophylactic 
therapy and the entire analysis period, while Al-Badriyeh et al90. defined it as the absence 
of initial antifungal discontinuation for the duration of the induction stage. Another 
example is the definition of IFI. Mauskopf et al106. defined this as having proven, 
probable, or presumptive IFI at 180 days post-therapy, whereas Grau et al109. followed 
the criteria of the European Organization for the Research and Treatment of Cancer and 
the Mycoses Study Group for defining patients with IFIs123. Appendix 10 includes further 
details on types of outcome measures used and their definitions.  
4.2.6. Source of Clinical Data 
Of the 19 articles, 16 extracted clinical data from published RCTs, where more than 
half of the studies (n=9) utilized the same RCT, by Cornely et al89. Details on the resources 
of clinical inputs in models are clarified in Appendix 10. The remaining three studies relied 
on data extracted from chart reviews90,91 or meta-analysis81 studies.  
4.2.7. Study Perspective 
Except for 4 articles that were based on the payer perpective83,87,102,105 and two 
articles that were based on the third party payer107,112, studies (n=13) adopted the hospital 
perspective, including medications, ICU stay, and hospital stay costs. However, the types 
of costs used were mostly inappropriate. While only direct medical costs were considered 
in all studies, six studies reported social perspectives of analysis. 
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4.2.8. Modeling and Time Adjustment  
89.5% of studies (n=17) included decision analysis modeling, including 9 Markov 
models for simulating the future use of medications. In the latter, discounting of cost was 
conducted, with the discount rate used being 3% in most studies, except in two articles that 
used discount rates of 1.5%129 and 5%105. One study, De Vries et al81. did not use neither 
discounting nor inflation, which they justified by a less than 1 year follow up where no cost 
adjustment is required. On the other hand, the study by O’Sullivan et al.102 utilized, as 
appropriate, both discounting and inflation. In the 10 studies that adjusted costs due to 
inflation, the consumer price index was appropriately used as relevant to the year of study.  
4.2.9. Sensitivity Analysis 
Sensitivity analysis was performed in all included articles. The majority of articles 
(n=11), however, used only one-way sensitivity analysis as the easiest to perform and 
understand, while the remaining combined the one-way analysis with two-way 
analysis107, multivariate109,111,113, or alternative scenario analyses102,90,91,129.  
4.2.10. Statistical Analysis 
Only 3 of all the included studies had some statistical analysis performed. The 
Kaplan–Meier analysis was applied by O’sullivan et al.102, the bootstrap resampling was 
conducted by Mauskopf et al.106, and the bootstrap procedure with a bias-corrected 
percentile method was performed by Sánchez-Ortega et al110. 
4.2.11. Quality Assessment of the Studies 
The CHEERS checklist was used to assess the reporting quality of the 
pharmacoeconomics evaluation articles included. Table 4.25 provides a summary of the 
quality assessment in all 19 articles. 
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Table 4.25. Quality assessment of included papers of pharmacoeconomics evaluations based on CHEERS checklist    
Section/Item Last author, date 
de 
Vries, 
2006 
Stam, 
2008 
Collins, 
2008 
Dranitsaris, 
2011 
Papadopoulos, 
2013 
Athanasakis, 
2013 
Grau, 
2012 
Michallet, 
2011 
Greiner, 
2010 
O’Sullivan
, 2009 
Title/Abstract/Introduction 
Title PA PA A A PA A A PA A A 
Abstract A PA A PA PA A A PA PA PA 
Background/objectives PA A A A PA A A A A PA 
Methods 
Target 
population/subgroups 
A A PA A A A A A A A 
Setting/location A A A A PA A A A A A 
Study perspective A A A A A A A A A A 
Comparators A A A PA NA NA A PA NA A 
Time horizon PA A A PA A A PA PA A A 
Discount Rate NA A NA NA A A A A A A 
Choice of health 
outcome 
A A A A A A A A A A 
Measurement of 
effectiveness 
A A A A A A A A A A 
Estimating resources 
and costs 
A A A PA A A A A A A 
Currency, price date, 
conversion 
A A A A A PA A A NA A 
Choice of model PA PA PA PA PA PA PA PA PA PA 
A: Adequate (information was explicitly presented in the text) 
PA: Partially adequate (information was NOT explicitly presented, but was suggested) 
NA: Not adequate (no information about the matter was available in the text) 
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Cont. Table 4.25. Quality assessment of included papers of pharmacoeconomics evaluations based on CHEERS checklist    
Section/Item Last author, date 
de 
Vries, 
2006 
Stam, 
2008 
Collins, 
2008 
Dranitsaris, 
2011 
Papadopoulos, 
2013 
Athanasakis, 
2013 
Grau, 
2012 
Michallet, 
2011 
Greiner, 
2010 
O’Sullivan, 
2009 
Title/Abstract/Introduction 
Assumptions A A A A A A A NA A A 
Analytical model PA PA PA PA PA PA PA PA PA PA 
Results 
Study parameters A A NA A A A A A A A 
Incremental costs 
and outcomes 
A A A A A A A A A A 
Characterizing 
uncertainty 
PA A A PA PA PA PA PA PA A 
Characterizing 
heterogeneity 
PA A A PA PA PA PA PA PA A 
Discussion/others 
Study findings, 
limitation, 
generalizability, 
current 
knowledge 
PA A A A A PA PA A A PA 
Source of 
funding 
A A NA A A A A A A A 
Conflict of 
interest 
A NA A NA NA A A A A NA 
A: Adequate (information was explicitly presented in the text) 
PA: Partially adequate (information was NOT explicitly presented, but was suggested) 
NA: Not adequate ( no information about the matter was available in the text) 
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Cont. Table 4.25. Quality assessment of included papers of pharmacoeconomics evaluations based on CHEERS checklist    
Section/Item 
Last author, date 
O’Sullivan, 
2012 
Schonfeld, 
2008 
Sohn, 
2009 
Mauskopf, 
2013 
Sánchez-
Ortega, 
2013 
de la 
Ca´mara, 
2009 
Heng, 
2013 
Al-
Badriyeh, 
2010 
Scharfstein, 
1997 
Title/Abstract/Introduction 
Title A PA A A A A A A PA 
Abstract PA A A PA A PA PA PA PA 
Background/objectives  A A A PA A A PA PA A 
Methods 
Target 
population/subgroups  
A A A A A A A A PA 
Setting/location  A A A A A A A A A 
Study perspective  A A A A A A A A A 
Comparators A A A PA A A A PA A 
Time horizon A A A A A A NA PA A 
Discount rate A NA NA NA NA A NA NA NA 
choice of health outcome  A A A A A A A A A 
Measurement of 
effectiveness  
A A A A A A A A A 
Estimating resources and 
costs 
A A A A A A A A A 
Currency, price date, 
conversion 
A A A A PA A A A A 
A: Adequate (information was explicitly presented in the text) 
PA: Partially adequate (information was NOT explicitly presented, but was suggested) 
NA: Not adequate (no information about the matter was available in the text) 
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Cont. Table 4.25. Quality assessment of included papers of pharmacoeconomics evaluations based on CHEERS checklist    
Section/Item 
Last author, date 
O’Sullivan, 
2012 
Schonfeld, 
2008 
Sohn, 
2009 
Mauskopf, 
2013 
Sánchez-
Ortega, 
2013 
de la 
Ca´mara, 
2009 
Heng, 
2013 
Al-
Badriyeh, 
2010 
Scharfstein, 
1997 
Choice of model  PA NA PA PA NA PA PA PA NA 
Assumptions A A A A NA A NA A A 
Analytical model  PA PA PA PA PA PA PA PA PA 
Results 
Study parameters A PA A PA PA PA PA A A 
Incremental costs and 
outcomes  
A A A A A A A A A 
Characterizing 
uncertainty 
PA PA PA A PA PA A A PA 
Characterizing 
heterogeneity  
PA PA PA A PA PA A A PA 
Discussion/others 
Study findings, 
limitation, 
generalizability, 
current knowledge  
PA A PA PA PA PA PA PA PA 
Source of funding  A A A NA A A A PA PA 
Conflict of interest  NA NA NA NA A A A NA NA 
A: Adequate (information was explicitly presented in the text) 
PA: Partially adequate (information was NOT explicitly presented, but was suggested) 
NA: Not adequate ( no information about the matter was available in the text) 
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CHAPTER FIVE: DISCUSSION 
 5.1. Phase 1: Pharmacoeconomics Evaluations of Posaconazole  
The current study was conducted as per the clinical practice of NCCCR, a public 
provider that is regulated, as part of HMC, by the Supreme Council of Health in Qatar. The 
selection of the drug formulary at the hospital is determined by the local Pharmacy and 
Therapeutic (P&T) Committee. Traditionally, and due to the perception of wealth, with 
Qatar having the highest income per capita in the world, the P&T committee of HMC 
mostly makes its decision based the safety and efficacy of drugs, with no much focus on 
cost-cutting measures. In recent years, however, due to increasing populations and pressure 
on unlimited healthcare budget, there has been an increasing interest in the economic 
considerations of therapies. The need for efficient therapies that cut costs to healthcare 
systems is particularly important in relation to medications such as systemic antifungals, 
where a global increase in the market value of antifungals is anticipated to increase to reach 
US$ 16.1 billion by 2021124. 
This is the first pharmacoeconomics evaluation in Qatar that evaluates the 
posaconazole utilization cost for prophylaxis against IFIs among hematologic malignancy 
patients undergoing chemotherapy or HSCT in NCCCR. The study consists of two 
evaluations, where Evaluation-I aims at determining the overall expenditure of using 
posaconazole at NCCCR, and Evaluation-II provides a cost-effectiveness analysis 
comparing posaconazole to fluconazole.  
In Evaluation-I, all eligible patients (n=70) from NCCCR were included in the 
analysis and followed up from the day of starting prophylaxis therapy until 112 days (4 
months) from the onset. A study population of 70 patients is consistent with other relevant 
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cost-analyses of medications in literature. A study was conducted in Germany by Rieger et 
al. enrolled 36 IFI patients vs. 72 control patients125, while Gedik et al. from Turkey 
included 126 patients receiving one of the three antifungals (voriconazole, LAMB, or 
caspofungin)126. All relevant directly utilized resources, including antifungal medications 
for prophylaxis and treatment, side effects management medications, hospitalization, and 
monitoring and diagnosing tests were considered in the study. The study was from the 
hospital perspective where only direct medical costs were accounted for. Direct 
nonmedical costs were difficult to include for the lack of reporting and documentation in 
the hospital records.  
As expected, patients with AML, being the most common hematological 
malignancy worldwide, constituted the majority of the included population (over 60%) 
followed by ALL patients (31.4%). Eventually, 73% of patients who failed prophylaxis 
therapy (n=30) due to getting IFIs were AML patients and 80% of patients who died before 
112 days (n=5) were also the ones diagnosed with AML. AML constituted the majority of 
many other similar studies as being the most common type of hematological cancer. In the 
Ullmman et al. study, for example, more than 67% of included patients had AML127. 
Another study conducted by Sánchez-Ortega had all 100% of the study population as AML 
patients128, while in the Stam et al. study, over 70% of included patients had AML129.  
The current thesis results are showing that effectiveness of posaconazole in 
preventing infection is relatively low (50% prophylaxis success without IFI or death in 112 
days). This seems lesser than the effectiveness of posaconazole in other settings. A study 
by Conely et al., for example, conducted in Germany, showed that the rate of IFI among 
posaconazole patients reached only 2%, with 16% death during the study89.  However, the 
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mean number of days of receiving prophylaxis in this study was much higher than that 
reported in similar other settings. For example, patients in NCCCR spent an average of 63 
days of prophylaxis, while this was reported in Australia to be 19 days in AML patients 
receiving posaconazole90.  The mean number of days of prophylaxis for patients who died 
before 112 days was 25 days in the current study, which is considerably shorter than the 
identified average duration of 63 days of prophylaxis. It seems that patients who died had 
much worse health status due to either being in advanced stage of malignancy or suffering 
from severe chemotherapy-related side effects. It is very difficult to ascertain the reason 
behind death in such a complex population, given that patients are receiving multiple 
medications for different indications, adding to the fact that the current documentation in 
Cerner® database in NCCCR does not report the reason behind death, whether death is 
because of specific type of fungal/bacterial/viral infection, major side effect intolerance, 
underlying disease, or cancer itself.  
With regards to the monitoring tests and diagnostic procedures that are performed 
for every single patient throughout the follow-up period, the study reveals that the hospital 
conducted more than 650 chest X-ray tests, 37 MRIs, 143 CT scans, 30 nuclear medicine 
tests, and 40 ultrasound tests for imaging. As for pathology tests, more than 1,600 tests 
were performed including 324 galactomannan tests, 771 blood culture tests, and 219 urine 
culture tests. Almost 14,000 tests were done for the monitoring of the patient organ status, 
including about CBC, ALT/AST, and creatinine levels. This is added to a cumulative cost 
of QAR 1,082,066, with measuring creatinine levels contributing to 43.1% of the cost. This 
is expected as patients with hematological malignancies are exposed to many factors that 
threaten their renal function, including the disease itself, chemotherapy, 
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immunocompromising medications, antimicrobial medications, etc. This was not 
consistent with other cost analysis studies as reported by Heimann et al., where diagnostic 
tests constituted only 3% of overall posaconazole cost69. Generally, only few papers 
reported costs of some diagnostic tests separately from the overall antifungal cost while 
none had accounted for costs spent on monitoring for safety aspects.  Nevertheless, it seems 
that the clinical practice in the NCCCR is missing an important parameter to monitor the 
safety and efficacy of the prophylaxis therapy, which is the monitoring of the posaconazole 
blood levels. The current model, therefore, did not account for the cost of the drug 
therapeutic monitoring (DTM) of posaconazole. Consistently, other cost analysis studies 
did not account for the cost of DTM110,125,126,109, although that the serum trough 
concentration measure of the posaconazole suspension is highly recommended by the 
IDSA due to the drug’s considerable variations (both interindividual and intraindividual) 
in bioavailability and drug-drug interaction130. About costs spent on monitoring of patients 
(for both safety and efficacy), negligible differences were observed among different 
possible patient outcomes.  
According to the decision analytic model in the study, NCCCR spent around QAR 
110,000 per patient when used posaconazole for prophylaxis. This high cost is only 
associated with posaconazole utilization in hematological malignancy patients and does 
not include costs of chemotherapy or any non-posaconazole related costs. Important is that 
half of this cost (QAR 55,000) is spent on managing the overall IFIs with prophylaxis 
failure, which raises a concern about how efficient the use of posaconazole for prophylaxis 
in NCCCR is. This is an important finding, especially as this is the first cost-analysis in 
literature to follow up the antifungals use to include the cost associated with potential 
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alternative therapies to IFIs failures. Other cost analyses of prophylaxis did not account for 
measuring costs of treating IFIs after prophylaxis failure and only reported the overall cost 
of prophylactic therapy69,109. Furthermore, the highest contributing patient pathway to 
overall cost, of all pathways, was the treatment and management of major hepatic ADR, at 
around 30% of the QAR 110,000. This was the result of only 13% of the patients in the 
success arm needing to stop their prophylaxis at some point in NCCCR for not tolerating 
the hepatic adverse effect of the drug, with these eventually exposed to higher risk for 
infection and, hence, an economic burden for the treatment of resulting probable/proven 
IFIs. This is another important finding in this study, especially as this is the first literature 
cost-analysis to follow up patients for the cost of consequences of ADR-specific 
discontinuations. In confirmation of the results, upon performing sensitivity analysis, only 
one variable revealed a major reduction in overall posaconazole expenditure (by 24%), 
which is eliminating major ADR costs by distributing its probability of occurrence to the 
minor and no ADR pathways. This only emphasizes the need for practices to consider the 
risk for major ADR in patients receiving posaconazole, and not just merely give 
posaconazole universally to all patients as is the case in NCCCR, Qatar.  
LAMB acquisition cost, as an alternative therapy, reached around QAR 140,000 
per month for either treating infections of seriously strong pathogens (Fusarium and 
Muocormyctes) or replacing posaconazole in case of hepatic disorders. However, 
Mucormycosis and Fusarium are rare fetal fungal infections, which have less than 3% 
probability (based on the expert panel) to occur in NCCCR patients, and, hence, their cost 
contribution in the overall model cost was less than 3.4% and 6.5%, respectively. Grau et 
al. also used only LAMB for IFI treatment if prophylaxis failed, where treatment costs 
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reached only QAR 47,171 (EUR 1 = QAR 4.49), indicating higher costs being spent in 
Qatari settings109. Gedik et al.  performed cost analysis study on treatment of IFI using 
caspofungin, voriconazole, and LAMB, where the combined expenditure of antifungals 
was reported to be QAR 65,662 per patient, a total expenditure of QAR 4,629,312 (USD 1 
= QAR 3.64)126.  
Given the limited availability of data of interest for the purpose of a comprehensive 
decision analytic model in this study, gaps in data were populated from literature as well 
as an expert panel. While the literature data was of an RCT that is of identical population 
and posaconazole use to those in the current study, and that the expert panel was made of 
relevant experts who provided ideal locally-specific and relevant data, the fact remains that 
such data are associated with uncertainty, which is a limitation in this study. Nevertheless, 
it is for this reason that a comprehensive multivariate Monte Carlo analysis was conducted, 
where the expert panel and RCT data were assigned ranges of uncertainty in the economic 
model of the study. With a narrow range of cost-outcome variation, however, between 
QAR 109,000 and 118,000, the uncertainty analysis demonstrated that the study outcome 
was robust and not sensitive to uncertainties. Other input uncertainties related to that the 
diagnostic tests may not necessarily relate to the antifungal use, and that the analytic model 
had assumed that the single posaconazole vial is not shared among different patients. Both 
of these concerns were evaluated, however; whereby, the model was re-run when 
accounting for not considering costs of tests for IFI diagnosis and for sharing the same 
posaconazole bottles between patients. Both scenarios did not significantly change the 
overall cost (93,815.9 and 108,894, respectively). 
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After looking at the absolute value of the cost of posaconazole use in the Qatari 
setting, it is only logical to also look at the relative value of posaconazole as compared to 
other prophylactic antifungals that are potentially beneficial. Hence, the Evaluation-II in 
the first phase of this thesis was to conduct a cost-effectiveness analysis that compares 
posaconazole to an alternative. Fluconazole was the other alternative as it showed 
effectiveness throughout several years in the same population among overseas 
settings86,91,102,111,129. As indicated earlier in the thesis, posaconazole is the only antifungal 
in consideration for prophylaxis in NCCCR. No other alternatives are considered, including 
fluconazole. Head-to-head comparative data of posaconazole versus fluconazole were, 
therefore, obtained from a major published RCT of 600 immunocompromised patients 
using either posaconazole or fluconazole, with a study population and a posaconazole 
administration standards that are identical to those in the NCCCR practice. The main 
findings in the RCT declared that posaconazole had similar efficacy to fluconazole in 
preventing IFI since the difference was not statistically or clinically significant. The 
effectiveness in the RCT was defined by survival without IFIs before the end of the 112 
days follow up. For the purpose of the current evaluation, however, as consistent with the 
local practices and as validated by the expert panel of the study, the success of interest was 
defined as survival for 112 days of receiving the first dose of prophylaxis without getting 
IFI and without having major ADR. The results from the current evaluation decision model 
were also that the rate of success between the two study drugs is minor. The study revealed 
a slightly higher effect of interest for posaconazole (0.76 vs. 0.75), but with much higher 
cost. Therefore, a DCEA was performed revealing that QAR 3,922,618 is to be saved with 
fluconazole over posaconazole per additional lost case of success with no major ADR.  
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While there is no defined threshold budget in Qatar, one can look at the 
international threshold budget provided by the World Health Organization (WHO) to be 
between QAR 365,000 to 547,500 (USD = QAR 3.65)131. The  DCER is, therefore, 
considered high and supports the use  of fluconazole over posaconazole in Qatar. There are 
no relevant DCER that is reported in literature, but looking at the ICER, a study in the USA 
revealed a much lower ICER of QAR 310,492 per IFI avoided and QAR 55,692 per life-
year saved that the ratio in the current study (USD 1= QAR 3.64)102. Similar results were 
shown by Ca´mara et al. as well with ICER of QAR 91,224 per life year gained (EUR 1 = 
QAR 4.49)111.  The ratio went even lower in Greece with QAR 29,089 per IFI avoided for 
posaconazole versus fluconazole/itraconazole (EUR 1 = QAR 4.49)132. However, one 
should consider the different outcome of interest from one study to another beside 
differences in overall costs of antifungal agent among different countries. This is very 
important and emphasizes the fact that outcomes of pharmacoeconomics evaluations are 
not readily generalizable to other settings, and that consistently reporting posaconazole as 
cost-effective against fluconazole in other settings, does not necessarily make 
posaconazole a cost-effective option in the Qatari setting, based on the Qatari practices of 
managing IFIs and major ADR.  
Looking at the breakdown of cost contributions based on the failure pathways 
where alternatives are given, one can see that the costs of alternative pathways were 
consistently higher with posaconazole as compared to fluconazole, except for the costs 
spent on treating aspergillosis infection in cases of failure due to IFIs (QAR 16,159 vs. 
28,727). This is explained by the fact that higher rate of prophylaxis failure due to 
aspergillosis infection among patients was reported with fluconazole, requiring further 
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hospitalization and management. This further emphasizes how important the local 
relevance is in the pharmacoeconomics evaluations; whereby, in a setting where Candida 
infections are more prevalent than Aspergillus infections, the relative cost of posaconazole 
will only further increase. Fluconazole is more effective against Candida than it is effective 
against Aspergillus infections91. 
Also emphasized in the current study is how important it is for decision-makers to 
consider the cost of alternatives besides the initial medication costs. This is as the former 
can overtake the latter in value. For example, in the posaconazole pathway where patients 
failed therapy due to Fusarium infection, the alternative therapies given (combination of 
voriconazole and LAMB) where way more costly than the initial posaconazole therapy 
(QAR 133,828 vs. 31,722). Similarly, as another example, following up on major ADR, 
LAMB was associated with a higher cost than the initial cost (QAR 50,871 vs. 39,131). As 
discussed in Evaluation-I, it is a strength that the current evaluation followed up 
consequences beyond the IFIs and ADR-specific outcomes, to also include alternative 
therapies given. No other relevant studies performed this in the literature. 
As discussed in Evaluation-I above, despite an occurrence rate of 8-11% only, the 
cost of success with major ADR contributed highly to the overall cost of antifungals (40-
45% with both study groups). Not accounting for major ADR, however, and unlike in the 
non-comparative cost analysis in Evaluation-I, did not affect the study outcome. This was 
anticipated given that the overall costs of both medications were similarly influenced by 
the respective value of major ADR.  
Also, as was discussed in Evaluation-I, the therapeutic drug monitoring of 
posaconazole is part of the standard patient management in overseas settings, but this was 
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not part of patient management in the current economic modeling of posaconazole use, 
which was due not being part of the standard practice in NCCCR. This, however, does not 
influence the study outcome as excluding it underestimates the cost of posaconazole as 
compared to fluconazole. This is when posaconazole is already associated with a higher 
cost as compared to fluconazole.  
As discussed earlier, while an expert panel was necessary to fill some gaps in data, 
it provided data that are inherently associated with uncertainty. Similar to insensitivity to 
major ADR, however, the study outcome was insensitive to the uncertainty in all key input 
variables investigated in the one-way and scenario analyses.  
Important is that, based on the Monte Carlo analysis, this study conclusion persisted 
in 96% of cases, with only in about 4% of cases, posaconazole dominated fluconazole. 
Also, DCER of fluconazole was over QAR 1,200,000 saved in 95% of cases.   
The decision analytic model in Evaluation-II of Phase-I was based on a published 
RCT. While this comes with the advantage of relying on a well-established methodology, 
with high internal validity due to randomization, blinding, and controlling of confounding 
factors133, the use of published RCTs comes with important limitations to the economic 
evaluation. First is the limited generalizability of results to the local setting due to the 
controlled nature of RCTs concerning the patient's criteria and the medication regimens134. 
Second, the specific duration that is pre-defined by the RCT might limit knowledge on 
important consequences and outcomes that could influence the overall cost of therapy. 
Mortality, requesting higher doses, switching to alternatives, and withdrawal due to 
intolerance are some examples of possible consequences and outcomes that might be 
missed in published RCTs. Nevertheless, for the purpose of the current evaluation, the 
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patient's characteristics and the drug administration in the RCT by Ullmann et al. are all 
identical to those in the local NCCCR setting. Also, the duration of follow up (4 months) 
is realistic, consistent with other studies as discussed earlier, and is appropriate to follow 
in this evaluation. Important is that the data was adopted to the local setting via a locally-
based expert panel. Even in the sensitivity analysis, which was conducted to increase the 
robustness and generalizability of studies, local hospitalization data from the NCCCR 
medical records were incorporated, as already discussed in Chapter 3.  
As noted above, a strength in both of Evaluation-I and Evaluation-II in Phase-I of 
this thesis is a decision analytic model that is more comprehensive than other models 
reported in the literature. The model represents all the possible consequences of using 
antifungal prophylaxis and, hence, an overall cost of prophylaxis that is more accurately 
measured. None of the previous studies accounted for the cost of treating the specific major 
and minor ADR with prophylactic antifungals. The only study that considered the cost of 
alternatives to side effects with prophylactic antifungals was that by Heng SC et al91. In 
this, however, all patients universally received LAMB in all cases on side effects, including 
the minor ones, such as nausea, vomiting, diarrhea, which could be easily treated with the 
much lesser costly over the counter medications (OTC).   
Despite outcome robustness in the current evaluations, outcomes can only be fully 
proven via a follow up future research that evaluates, whether prospectively or 
retrospectively, the comparative clinical and economic impacts of posaconazole and 
fluconazole for prophylaxis against IFIs in immunocompromised patients with 
hematological malignancies, and undergoing chemotherapy or HSCT, at local Qatari 
NCCCR setting. This, however, is obviously very difficult currently as fluconazole is not 
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available as a prophylactic option in the NCCCR. Locally-specific posaconazole studies, 
like the current ones, are therefore considered important for the quality assessment of local 
practices. It seems that fluconazole is equally effective to posaconazole, including based 
on local interests and practices, with a considerable anticipated amount of cost-savings. 
Adding fluconazole to the arsenal of available systemic antifungals for the prophylaxis 
against IFIs in cancer patients can only be beneficial and will enable the availability of 
local fluconazole data that can be then utilized into locally-based and relevant head-to-head 
evaluations between the prophylactic posaconazole and fluconazole in the NCCCR setting.   
 5.2. Phase 2: Systematic Review of Methodological Trends and Gaps, and the 
Reporting Quality of Comparative Economic Evaluations on the Use of Systemic 
Antifungal Agents Used for Prophylaxis Against IFI  
Phase-2 of this thesis was a comprehensive thematic systematic review that focused 
on the literature designs and methods used in the pharmacoeconomics evaluations of 
systemic antifungal agents for prophylaxis indication against IFI among 
immunocompromised patients. The reason this comes as the last component of this thesis 
is that, as discussed earlier, this systematic review is not to review the literature to identify 
gaps in knowledge. Gaps that research in the current thesis will look to partially or entirely 
fix. Based on the research in Phase-1 and other relevant literature, this systematic review 
is meant to identify methodological limitations, hence, make recommendations for future 
research in the field.  
This systematic review is the first to identify the characteristics, trends and 
reporting quality of published research in economic evaluations about the use of systemic 
antifungals. The current systematic review is the first to give recommendations for future 
 117 
 
pharmacoeconomics studies to consider, within the context of antifungal agents for the 
immunocompromised population, by comprehensively identifying methodological gaps in 
the current literature. A review by Pechlivanoglou et al. focused on cost-benefit and cost-
effectiveness of all studies of antifungals for prophylaxis71. While a review by Wilke 
focused on echinocandins only regardless of the purpose of use, whether it is for treatment 
or prophylaxis84, a review by Lyseng-Williamson only focused on posaconazole for 
prophylaxis among any immunocompromised condition including cancer135. These 
reviews were looking to summarize recommendation about practices and did not look at 
trends and gaps of methodological aspects.  
This review analyzed 19 publications of economic evaluations of systemic 
antifungals. While studies answered the questions that they were performed to answer, 
there was a wide range of methodological trends and gaps that existed in these studies. It 
seems that studies did not adhere well to current standards for conducting and reporting 
economic evaluations, such as those by the Panel of cost-effectiveness in health and 
medicine136 or by the British Medical Journal’s guidelines for economic submissions. This 
mostly resulted in different ranges of ICERs, limiting the robustness of the body of 
evidence and the guidance to decision-makers in other settings. This mostly led to that 
different conclusions were made for the same medication in various studies for the same 
use; whereby it is hard for decision-makers to come up with aggregate evidence in favor 
or against any antifungal option.  
Perspective. The utilization of health care and patient resources, including work 
productivity, are expected to be largely affected in cancer populations. Only 4 studies, 
however, identified the social perspective as of interest in their evaluations. The majority 
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of studies were from hospital and payer perspectives, which are common perspective, 
mostly due to convenience, and typically includes the direct medical type of costs. What is 
Important is that those studies with the social perspective only included the direct medical 
costs, with no non-medical or productivity costs involved. This is an inappropriate 
interpretation of what the social aspect entails in studies.  
Modeling. All 19 studies included decision analytic modeling, which is appropriate 
as modeling is essential for better understanding the different effects and costs of an 
intervention. However, the validity of a model and its results rely on the evidence and 
assumptions it is based on. About the evidence, all included studies were non-experimental 
in design, where studies extracted data from secondary sources. In fact, the majority of 
modeling studies relied on the same sources of data, which were few published 
RCTs89,103,110,137. This is a limitation as prospective RCTs would have generated more 
robust and convincing evidence for the local setting. Even if RCTs are not feasible due to 
limitations in resources, the incorporation of locally-based data from local medical records 
and expert panels would have provided more relevant results. 
Markov modeling. Markov models are ideal for pharmacoeconomics evaluations 
in a recurrent condition such as fungal infections in cancer papers, where the Markov model 
has an advantage over decision analytic models in incorporating longer time horizons. It 
extends the results of clinical trials and extrapolates intermediate endpoints into final 
outcomes. It seems, however, that authors in studies were not consistently interested in the 
long-term horizon follow up durations as about 9 of the included 19 studies included 
Markov modeling. What is believed to have contributed to this limited use of Markov 
design is the existing gaps in the local clinical and quality of life data and evidence to use 
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in populating the longer horizon multi-state model. In relevance to Markov modeling, 
discounting is required to adjust future values of variables to their current values. Except 
in one study by de Vries et al.81, this was conducted in studies, with the discount rate 
varying from 1.5%129 and 5%105, but with no justification given to any. 
Reporting of cost. It is important that the cost components and measuring 
approaches are clearly reported in studies. This is to enable the reproducibility and 
applicability of results. While all included 19 studies identified costs considered, studies 
did not provide details of how these were calculated. For example, none of the studies 
indicated whether costs used are hospital charges or costs. Hospital charge is not an ideal 
estimation of cost as this is decided on to compensate for the cost of other services and 
facilities provided by the hospital setting. Using charges instead of costs produces less 
accurate conclusions. 
QALY. QALY is crucial in most chronic diseases, and of particular importance in 
cancer patients, where QALY is a widely preferred summary multidimensional value of 
outcomes in pharmacoeconomics. It incorporates trade-offs between quality of life and 
quantity of life in a common metric.  
Outcomes. Despite the importance of health states, such as success, failure and 
death, in decision making, QALY is also essential to consider in cases of chronic patient 
management and follow up, incorporating trade-offs between quality of life and quantity 
of life in a common metric. While several studies did indeed develop Markov models to 
follow up the longer horizon of outcomes, only one study identified and measured the 
QALY as the outcome of interest in a study129. Outcomes are increasingly multi-
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dimensional, and only focusing on health status outcomes, instead of both QALYs and 
specific health states, is a shortcoming that requires attention. 
Adverse drug reactions. Drug-related adverse events have a significant influence 
on the direct cost and cost-effectiveness and, hence, are anticipated to be of primary 
consideration when differentiating between medications. While only one study included 
the analysis of adverse event costs91, however, the study did not model discontinuations 
due to adverse events. The extent of the discontinuation and its cost are not clear in studies, 
which was also not included in sensitivity analyses conducted. To consider the side effects 
that are associated with discontinuations as equivalent to those that are not is inappropriate 
when guiding decision making.  
Sensitivity analyses. Sensitivity analysis is a crucial component in economic 
evaluations, to investigate the robustness of outcomes made and also increase their 
generalizability. While all studies included sensitivity analyses, however, these did not 
justify input changes made. Importantly, sensitivity analyses were limited in variability. 
Only the one-way analysis was conducted, and none of the studies utilized a combination 
of methods that additionally includes the multivariate and scenario analyses. In the absence 
of correlation, the one-way analysis underestimates uncertainty, even if interpreted 
correctly138.  
Quality of reporting. The quality of reporting varied in relation to different aspects 
of the studies. Partially adequate reporting of aspects such as the analytical model, 
characterizing uncertainty and characterizing heterogeneity, study findings, and limitations 
and generalizability, was in 63% to 100% of studies. Only 16% of studies did not report 
adequate information about the study competitors and choice of model, and 5% of the 
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studies did not mention the study time horizon. Aspects such as the setting and location, 
perspective, selection of health outcome, estimating resources and costs, and incremental 
costs and outcomes, were adequately reported in 100% of the studies. 52% of studies did 
not sufficiently report enough information on discount rate choice and conflict of interest 
in studies. 
Study comparators. Most of the comparisons in studies were made of expensive 
medications versus cheaper older ones and, also, more than 90% of these included the azole 
class, e.g. posaconazole. These studies, and unlike in the current thesis, have therefore 
mostly reported a state of dominance in favor of the newer medications, in 14 out of the 19 
articles. More economic evaluations should be aiming to compare among the newer, more 
expensive medications, such as those of the echinocandins versus azoles81,87. There is also 
a lack of ‘head-to-head’ trials among new antifungal agents for prophylaxis that include 
more recent agents, such as micafungin. Without head-to-head studies of micafungin 
versus posaconazole, as an example, it is difficult to build economic evaluations that 
provide robust comparative data of the agents. 
Definition of health states. Different types of outcome measures were considered 
among the various studies. For example, while some studies looked at the absence of IFIs 
as the primary outcome, others looked at survival after prophylaxis when made their 
conclusions81,82,88,102. Even when studies targeted the same outcome measure, the definition 
of the measure differed. For example, while “successful therapy” was defined as the 
absence of IFI during prophylaxis in studies, it was determined as the absence of 
discontinuation of prophylaxis during induction therapy in others82,83,91. This, however, is 
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anticipated to a degree seeing that the choice for outcome measure and its definition are 
primarily driven by the local interests of decision makers in practices.  
Suggestions for Future Research  
Based on the current systematic review, several recommendations for improving future 
evidence can be made.  
 Reporting of study details should be enhanced in published reports. Important features 
can include modeling assumptions, costing components and methods, discount rate, and 
sensitivity analysis. There are several quality assessment checklists that authors can use 
to enhance reporting of essential aspects of economic studies. These include the 
CHEERS reporting checklist139.  
 Research evaluations should enhance their adherence to good practices when designing 
new studies, including about methodological concerns regarding modeling, the source 
of data, sensitivity analysis, cost versus perspective, outcome measures, and side effects. 
This can be via using existing good practice guidelines, such as the health economic 
evaluation (HEE) quality appraisal instrument and those posed by the international 
society of pharmacoeconomics and outcome research (ISPOR)139,140,141. 
 Journal reviewers and editors should push for more reliable and justified measures for 
assessing and defining study outcomes, to improve uniformity among studies and enable 
a cumulative evidence generation. 
 Economic evaluations should incorporate more of head-to-head comparisons between 
the newer most expensive antifungal agents. If not as a primary source of comparative 
economic data, the evaluations can be clinical at least, which can be built on via 
simulation models to generate economic outcomes in different settings.  
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 Future research can benefit from studies that better consider the non-medical costs of 
therapies. This achieves consistency among costs examined and reported, and helps 
compile a better understanding of the social impact of being on medications. To enhance 
the availability of data for such a purpose, future research in local settings should better 
document and audit social effects of long-term therapies, including the association 
between intermediate and final outcomes of interest.  
 Quality of life considerations in cost-effectiveness evaluations of long-term antifungal 
prophylaxis needs to increase in literature. QALY can be more considered when 
assessing therapies, instead of focusing on clinical health states only. 
 All economic evaluations conducted in studies compared the different comparators 
against the prophylactic indication only. Different antifungals, however, can also have 
different levels of effectiveness against other indications of interest at the same practice 
setting. Recent methods such as the multi-criteria decision modeling should be used, 
therefore, to enable a more efficient selection of antifungals; whereby, these will be 
compared based on their overall performance against multiple criteria and indications 
at the same time in the same setting. 
Study Limitations  
There are several limitations in the current review. The literature search was 
restricted to the English language, which may exclude relevant studies in other less 
common languages such as Chinese, French, and German. However, authors do not have 
the ability or the resources to translate the non-English literature. Moreover, despite the 
comprehensive search via several important search engines in this review, additional search 
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terms and/or combinations among them are possible and can lead to identifying additional 
studies that were missed in the current review.  
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CHAPTER SIX: CONCLUSION 
  
Posaconazole is the first and only systemic antifungal that is in consideration at the 
NCCCR in Qatar for prophylaxis against IFIs in the immunocompromised hematology 
patients. Within the context of this setting, the current research includes (i) the first cost-
analysis simulation model of posaconazole and the resource utilization associated with it, 
and (ii) the first decision analytic cost-effectiveness simulation model of posaconazole 
versus fluconazole, in Qatar and the region. Internationally, the constructed models are 
comprehensive, and the first to consider ADR and the discontinuations associated with 
them, and they are also the first to follow up on specific alternative therapies to failures 
and discontinuations.  
In the Qatari setting, 43% of patients on prophylactic posaconazole fail therapy due 
to IFIs, with the most common of which due to Candida infections. The overall cost of a 
patient on posaconazole was QAR 109,802, with the proportional cost per success being 
QAR 52,029 per patient. The main cost driver in the use of posaconazole was the patient 
pathway of success with major ADR, contributing to 30% of the total cost. Compared to 
posaconazole, fluconazole was associated with about similar rate of success without major 
ADR, but at a much-reduced cost. In 96% of cases, fluconazole saved over QAR 1,200,000 
compared to posaconazole per lost case of success without major ADR.  
The findings of this research are in contrast to the current practices at the NCCCR 
in Qatar, where posaconazole is the only systemic antifungal to be ever considered for 
prophylaxis. Based on the results in this study, particularly the comparative against 
fluconazole, it is possible that other antifungals, such as fluconazole, can be considered for 
 126 
 
addition to the prophylactic arsenal in NCCCR, to maybe replace posaconazole in patients 
with high risk for ADR.  
In addition, the research identified several aspects of methods where 
recommendations for future research were made. These included aspects about modeling 
and follow up, cost and perspective, comparators and outcomes, sensitivity analysis, and 
the quality of reporting. 
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APPENDICES 
Appendix 1. Ethical Approval Letter, Phase-I Of Thesis 
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Appendix 2. Qatar University Ethics Exemption Letter, Phase-I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 148 
 
Appendix 3. Data Collection Form, Evaluation-I, Phase-I Of Thesis 
Project title: cost-analysis study that evaluate the cost of resource utilization associated with the use of prophylaxis 
(posaconazole) 
Table 1: Patient demographics  
Subject NO. Patient age (years) Sex (M=1, F=2) Weight (KG) 
 
Table 2: Medical information 
Underlying 
disease 
Date of 
diagnosi
s with 
cancer 
Current or 
previous 
history of 
proven or 
probable 
IFI 
(Yes=1, 
No=2) 
Have used 
systemic 
antifungals 
within 7 
days prior to 
commencing 
posaconazol
e 
Chemotherapy 
protocol 
received  
Date of 
admission  
Date 
of 
disch
arge 
Prophylaxi
s drug 
name 
Dose
(mg) 
Formulation Frequenc
y (n/day) 
Duration 
(day) 
 
Table 3: Patient co-morbid conditions 
HIV/AIDS Diabetes HTN CVD Thyroid Asthma Arthritis Epilepsy Depression None 
 
Table 4: Smoking status 
Current Never Ex-smoker Unknown 
 
Table 5: Monitoring tests for side effects  
NO. of LFT 
(ALT/AST) 
Notes NO. of 
RT(creatinin) 
Notes NO. of 
CBC 
Notes Other tests 
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Table 6: Screening test for fungal infection (imaging) 
x-ray 
scan 
type 
NO. CT 
scan 
type 
NO. Ultrasound 
type 
NO. MRI 
type 
No. Nuclear 
medicine 
test type 
No. Cardiology 
procedures 
types 
No. 
 
Table 7: Screening test for fungal infection (pathology) 
Urine 
culture No. 
Stool 
culture No 
Blood 
culture No. 
Parasites 
stool 
Acid fast 
bacili 
culture  
C. Diff 
toxin 
C. Coli 
antigen test 
Galactomannan 
test 
PCR 
virology  
 
Table 8: Patient outcome status  
alive W/O IFI after 112 days alive with IFI before 112 days  death related/unrelated to IFI-
date 
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Appendix 4. Questions for Expert Panel Discussions, Phase-I of Thesis  
1. Availability of posaconazole in bottle (mg):  
2. Availability of fluconazole tables in box:  
3. Do you share bottles or boxes between patients if the amount allow that?  
4. Based on your experiences in Qatar, in relation to patients taking posaconazole, 
what are types of fungal infection that you may see in addition to Aspergillus and 
Candida 
1. … 
2. … 
3. … 
 
4.1 What are the probabilities of these to happen? 
a. Aspergillosis :  
b. Candidiasis:  
c. Other #1:  
d. Other #2:  
e. Other #3:  
f. Other #4: 
 
5. In relation to patients taking fluconazole, what are types of fungal infection that 
you see in addition to Aspergillus and Candida (flu is only given in lymphoid 
malignancy- same pathogens)  
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5.1 What are the probabilities of these to happen? 
a. Aspergillosis:  
b. Candidiasis:  
c. Other #1:  
d. Other #2:  
e. Other #3:  
f. Other #4: 
 
6. If proven/ probable aspergillosis infection is detected  during posaconazole 
prophylaxis,  what antifungal therapy do you switch to: 
a. Drug name:  
b. Formulation:  
c. Dose:  
d. Frequency:  
e. Availability in bottle (mg):  
7. If proven and probable IFI , may you provide alternative to flu  in case of 
aspergillosis infection:  
a. Drug name:  
b. Formulation:  
c. Dose:  
d. Frequency:  
e. Availability in bottle (mg):  
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8. If proven and probable IFI , may you provide alternative to posa in case of 
candida infection: 
a. Drug name:  
b. Formulation:  
c. Dose:  
d. Frequency:   
e. Availability in bottle (mg):  
9. If proven and probable IFI , may you provide alternative to flu in case of candida 
infection: 
a. Drug name:  
b. Formulation:  
c. Dose:  
d. Frequency:   
e. Availability in bottle (mg):  
10. If proven and probable IFI , may you provide alternative to posa in case of other 
type of infection: 
a. Infection type#1:  
b. Drug name:  
c. Formulation:  
d. Dose:  
e. Frequency:  
f. Availability in bottle (mg):  
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11. If proven and probable IFI , may you provide alternative to posa in case of other 
type of infection: 
a. Infection type#2:  
b. Drug name:  
c. Formulation:  
d. Dose:   
e. Frequency:  
f. Availability in bottle (mg):  
12. If proven and probable IFI , may you provide alternative to posa in case of other 
type of infection: 
a. Infection type#3:  
b. Drug name:  
c. Formulation:  
d. Dose:  
e. Frequency:  
f. Availability in bottle (mg):  
13. If proven and probable IFI , may you provide alternative to flu in case of other 
type of infection: 
a. Infection type#1:  
b. Drug name: 
c. Formulation: 
d. Dose: 
e. Frequency: 
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f. Availability in bottle (mg):  
14. If proven and probable IFI , may you provide alternative to flu in case of other 
type of infection: 
a. Infection type#2:  
b. Drug name: 
c. Formulation: 
d. Dose: 
e. Frequency: 
f. Availability in bottle (mg):  
15. If proven and probable IFI , may you provide alternative to flu in case of other 
type of infection: 
a. Infection type#3:  
b. Drug name: 
c. Formulation: 
d. Dose: 
e. Frequency: 
f. Availability in bottle (mg):  
16. Treatment of severe headache side effect during prophylactic posaconazole: 
a. Drug name:  
b. Formulation:  
c. Dose:  
d. Frequency:  
e. Duration (day):  
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f. Availability in bottle (mg):   
17. Treatment of severe headache side effect during prophylactic Fluconazole: 
a. Drug name:  
b. Formulation:  
c. Dose:  
d. Frequency:  
e. Duration (day):  
f. Availability in bottle (mg):   
 
 
18. Treatment of GI side effect (with posaconazole): 
 Diarrhea Nausea Vomiting 
Drug name   
Dose:    
Formulation:     
Frequency:    
Duration 
(day): 
   
Availability 
in bottle 
(mg):  
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19. Treatment of GI side effect (with fluconazole):  
 Diarrhea Nausea Vomiting 
Drug name    
Dose:    
Formulation:     
Frequency:    
Duration 
(day): 
   
Availability 
in bottle 
(mg):  
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20. Treatment of liver & biliary side effects due to antifungal therapy (with 
posaconazole): 
 Bilirubinemia Increased 
γ-
glutamyltra
nsferase 
Increased 
hepatic 
enzymes 
Increased 
aspartate 
aminotransferase 
Increased alanine 
aminotransferase 
Drug name  
Dose:  
Formulation:   
Frequency:  
Duration 
(day): 
 
Availability 
in bottle  
(mg):  
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21. Treatment of liver & biliary side effects due to antifungal therapy (with 
fluconazole):  
 Bilirubinemia Increased 
γ-
glutamyltr
ansferase 
Increased 
hepatic 
enzymes 
Increased 
aspartate 
aminotransfera-
se 
Increased alanine 
aminotransferase 
Drug name      
Dose:      
Formulation:       
Frequency:      
Duration 
(day): 
     
Availability 
in bottle  
(mg):  
     
 
22. Based on your experience in Qatar, what are adverse events with prophylactic 
posaconazole that can lead to therapy discontinuation and what is your estimation 
of the probabilities of these to happen? 
SE#1:    Probability:  
SE#2:     Probability:  
For fluconazole :  
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23. How often does a patient discontinue due to oral therapy intolerance? And what 
do you give instead in case of posaconazole and fluconazole? 
24. In your experience, during a hospital stay for immunocompromised patients with 
neutropenia with fever, how often would a patient spend a day in the ICU? 
(Average number of days per week or month) 
25. Info of tests done for patients: Which of the following tests would you use to 
monitor for prophylaxis efficacy from invasive fungal infections, and how often 
do you use the tests for the same patient (per day, week or month)? (check all 
that apply) 
Test Applied or not Frequency (in Ward) Frequency (in ICU) 
Chest X-Ray    
CT scan    
Ultrasound scan    
MRI scan    
Blood C&S    
Urin C&S    
Non-Blood C&S    
Bronchoscopy    
lung biopsy    
skin biopsy    
lung wedge 
resection 
   
lumbar puncture    
PCR    
Serology    
Histology    
full blood count    
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renal function test    
liver function test    
Galactomannan 
test 
   
Coagulation test    
CRP    
fibrinogen     
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Appendix 5. Search Strategy, Pubmed, Phase-Ii of Thesis 
 
 
Search Strategy: 
 
#  
 
Searches Results 
1 ("Antifungal Agents"[Mesh] OR "Pre-Exposure Prophylaxis"[Mesh] OR 
prophylaxis) AND ("Mycoses"[Mesh] OR "Lung Diseases, 
Fungal"[Mesh] OR "Immunocompromised Host"[Mesh] OR 
"Neoplasms"[Mesh] OR Systemic OR invasive OR ) AND ("Cost-Benefit 
Analysis"[Mesh] OR "Economics"[Mesh] OR "Costs and Cost 
Analysis"[Mesh]). Limited to journal articles  
5139 
2 ("Antifungal Agents"[Mesh] OR "Pre-Exposure Prophylaxis"[Mesh] OR 
prophylaxis) AND ("Mycoses"[Mesh] OR "Lung Diseases, 
Fungal"[Mesh] OR "Immunocompromised Host"[Mesh] OR 
"Neoplasms"[Mesh] OR Systemic OR invasive OR ) AND ("Cost-Benefit 
Analysis"[Mesh] OR "Economics"[Mesh] OR "Costs and Cost 
Analysis"[Mesh]). 
5132 
3 Limit 1 to journal articles, human, English language, and title and abstract 385 
4 Limit 2 to RCT, Comparative articles, systematic reviews, meta analysis,  191 
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Appendix 6. Literature Data Collection Form, Phase-Ii of Thesis  
 
Record number: 
Reviewer: 
- Checked by: 
Date of review: 
Author (All): 
Year of Paper: 
Journal (Full, In Abbreviation): 
Title: 
Volume/issue: 
Method of Economic Evaluation (Cost Minimization, Cost Effectiveness, Cost Utility, 
Cost Benefit, cost analysis): 
Comparative: Y / N 
Intervention: 
Comparator: 
Country: 
Population (Disease): 
Participants: 
- Age:  
- Inclusion: 
- Exclusion: 
Sample Size (Intervention, Comparators): 
 
Clinical Effectiveness Component 
Study setting: 
Clinical Effectiveness Data: 
- Clinical Measure: 
o Definition: 
Source of Effectiveness Data: 
Time Horizon of Follow up:  
Analysis Used: 
Clinical Outcome Results: 
 
Economic Effectiveness Component 
Perspective: 
Study setting: 
Date of Analysis: 
Dates of Economic Data: 
Type of Time Adjustment (Inflation, Discounting): 
Discount Rate: 
Source of Economic Data: 
Modeling: 
- Type (Decision Analysis, Markov Model) 
- If Markov,  
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o Health States Considered: 
o Utility of these: 
- Structure (Branches and Different Pathways) 
Direct Medical Costs: 
Direct non-Medical Cost: 
Indirect Costs: 
Measure of Benefit Used in Economic Evaluation: 
Treatment of Uncertainty (Sensitivity Analysis): 
- Inputs Varied (Clinical, Cost, Utility): 
- Range of Variation: 
- Types of Sensitivity Analysis (One-Way, Mutivariate, Scenario): 
- Graphical Presentation of Results: 
- Conclusions of Sensitivity Analysis: 
Statistical Analysis: 
Main Economic Findings: 
Outcome Category: 
 Higher Effect  Same Effect  Lower Higher 
Higher Cost    
 Same Cost    
Lower Cost    
 
Authors Conclusions: 
Reviewers Comments:  
- Reviewer Name: 
o Comment: 
- Reviewer Name:  
o Comment: 
Initial Extraction Complete Yes___  No___ 
Revision Complete Yes___  No___ 
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Appendix 7. Prisma 2009 Checklist 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; 
results; limitations; conclusions and implications of key findings; systematic review registration 
number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.   
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale.  
 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors 
to identify additional studies) in the search and date last searched.  
 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that 
it could be repeated.  
 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta-analysis).  
 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data from investigators.  
 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
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Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.   
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 
16]).  
 
DISCUSSION   
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).   
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  
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Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
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Appendix 8. Cheers Checklist  
 
Section/item Item 
No 
Recommendation Reported on 
page No/line 
No 
 
Title 1 Identify the study as an economic evaluation or use more specific terms such as 
“cost-effectiveness analysis”, and describe the interventions compared. 
 
Abstract 2 Provide a structured summary of objectives, perspective, setting, methods 
(including study design and inputs), results (including base case and uncertainty 
analyses), and conclusions. 
 
 
Background and 
objectives 
3 Provide an explicit statement of the broader context for the study. 
Present the study question and its relevance for health policy or practice decisions. 
 
 
Target population and 
subgroups 
4 Describe characteristics of the base case population and subgroups analysed, 
including why they were chosen. 
 
Setting and location 5 State relevant aspects of the system(s) in which the decision(s) need(s) to be made.  
Study perspective 6 Describe the perspective of the study and relate this to the costs being evaluated.  
Comparators 7 Describe the interventions or strategies being compared and state why they were 
chosen. 
 
Time horizon 8 State the time horizon(s) over which costs and consequences are being evaluated 
and say why appropriate. 
 
Discount rate 9 Report the choice of discount rate(s) used for costs and outcomes and say why 
appropriate. 
 
Choice of health 
outcomes 
10 Describe what outcomes were used as the measure(s) of benefit in the evaluation 
and their relevance for the type of analysis performed. 
 
Measurement of 
effectiveness 
11b Synthesis-based estimates: Describe fully the methods used for identification of 
included studies and synthesis of clinical effectiveness data. 
 
Measurement and 
valuation of preference 
based outcomes 
12 If applicable, describe the population and methods used to elicit preferences for 
outcomes. 
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Section/item Item 
No 
Recommendation Reported on 
page No/line 
No 
Estimating costs and 
resources 
13b Model-based economic evaluation: Describe approaches and data sources used to 
estimate resource use associated with model health states. Describe primary or 
secondary research methods for valuing each resource item in terms of its unit 
cost. Describe any adjustments made to approximate to opportunity costs. 
 
Currency, price date and 
conversion 
14 Report the dates of the estimated resource quantities and unit costs. Describe 
methods for adjusting estimated unit costs to the year of reported costs if 
necessary. Describe methods for converting costs into a common currency base 
and the exchange rate. 
 
Choice of model 15 Describe and give reasons for the specific type of decision-analytical model used. 
Providing a figure to show model structure is strongly recommended. 
 
Assumptions 16 Describe all structural or other assumptions underpinning the decision-analytical 
model. 
 
Analytical methods 17 Describe all analytical methods supporting the evaluation. This could include 
methods for dealing with skewed, missing, or censored data; extrapolation 
methods; methods for pooling data; approaches to validate or make adjustments 
(such as half cycle corrections) to a model; and methods for handling population 
heterogeneity and uncertainty. 
 
 
Study parameters 18 Report the values, ranges, references, and, if used, probability distributions for all 
parameters. Report reasons or sources for distributions used to represent 
uncertainty where appropriate. Providing a table to show the input values is 
strongly recommended. 
 
Incremental costs and 
outcomes 
19 For each intervention, report mean values for the main categories of estimated 
costs and outcomes of interest, as well as mean differences between the 
comparator groups. If applicable, report incremental cost-effectiveness ratios. 
 
Characterising 
uncertainty 
20b Model-based economic evaluation: Describe the effects on the results of 
uncertainty for all input parameters, and uncertainty related to the structure of the 
model and assumptions. 
 
Characterising 
heterogeneity 
21 If applicable, report differences in costs, outcomes, or cost-effectiveness that can 
be explained by variations between subgroups of patients with different baseline 
characteristics or other observed variability in effects that are not reducible by 
more information. 
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Section/item Item 
No 
Recommendation Reported on 
page No/line 
No 
Study findings, 
limitations, 
generalisability, and 
current knowledge 
22 Summarise key study findings and describe how they support the conclusions 
reached. Discuss limitations and the generalisability of the findings and how the 
findings fit with current knowledge. 
 
 
Source of funding 23 Describe how the study was funded and the role of the funder in the identification, 
design, conduct, and reporting of the analysis. Describe other non-monetary 
sources of support. 
 
Conflicts of interest 24 Describe any potential for conflict of interest of study contributors in accordance 
with journal policy. In the absence of a journal policy, we recommend authors 
comply with International Committee of Medical Journal Editors 
recommendations. 
 
 
 
 
 
 
  
 170 
 
Appendix 9. Decision Trees as Presented in Included Systematic Review Articles, Phase-Ii of Thesis 
Recor
d No.  
Author’s last 
name, year 
Screenshot of decision tree 
1 de Vries, 
2006 
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2 Stam, 2008 
 
 172 
 
3 Collins, 2008 
 
 173 
 
4 Dranitsaris, 
2011 
 
 174 
 
5 Papadopoulos
, 2013 
 
 175 
 
6 Athanasakis, 
2013 
 
 176 
 
7 Grau, 2012 
 
 177 
 
8 Michallet, 
2011 
 
 178 
 
9 Greiner, 2010 
 
 179 
 
10 O’Sullivan, 
2009 
 
 180 
 
11 O’Sullivan, 
2012 
 
12 Schonfeld, 
2008 
No tree provided 
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13 Sohn, 2009 
 
 182 
 
14 Mauskopf, 
2013 
 
15 Sánchez-
Ortega, 2013 
No tree provided 
 183 
 
16 de la 
Ca´mara, 
2009 
 
 184 
 
17 Heng, 2013 
 
 185 
 
18 Al-Badriyeh, 
2010 
 
 186 
 
19 Scharfstein, 
1997 
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Appendix 10 Outcome Measure of All Included Systematic Review Articles, Phase-Ii of Thesis 
 
Clinical Effectiveness Data 
Author’
s last 
name, 
year 
Study 
Setting 
Clinical measure  Definition Source of effectiveness data 
O’Sulliv
an, 2009 
89 Clinical 
centers 
worldwide 
 
Proven or probable 
invasive fungal infection 
IFI 
 
 
According to consensus criteria of the 
European Organization for the 
Research and Treatment of Cancer and 
the Mycoses Study Group 
Cornely OA, Maertens J, Winston DJ, et al. 
Posaconazole vs. fluconazole or itraconazole 
prophylaxis in patients with neutropenia. N 
Engl J Med 2007;356:348-59 
Greiner, 
2010 
Hospital IFI occurrence, IFI-related 
death and death from other 
causes 
 
-- Wingard JR, Piantadosi S, Vogelsang GB, 
Farmer ER, Jabs DA, Levin LS, Beschorner 
WE, Cahill RA, Miller DF, Harrison D: 
Predictors of death from chronic graft-
versushost disease after bone marrow 
transplantation. Blood 1989;  7 4:  1 428–1435. 
1 
Kantarjian H, Beran M, Cortes J, O’Brien S, 
Giles F, Pierce S, Shan J, Plunkett W, Keating 
M, Estey E: Long-term follow-up results of the 
combination of topotecan and cytarabine and 
other intensive chemotherapy regimens in 
myelodysplastic syndrome. Cancer 2006;  1 06:  
1 099–1109. 
National Cancer Institute: SEER cancer 
statistics review 1975–2004. http://seer.cancer. 
gov/csr/1975_2004/sections.html (accessed 
January 15, 2008). 
Sánchez-
Ortega, 
2013 
Hospital IFIs avoided and overall 
survival 
Defined by the European Organization 
for Research and Treatment of Cancer 
criteria 
 
They conducted an observational study at the 
Catalan Institute of Oncology, Hospital Duran i 
Reynals, Barcelona, Spain Sanchez-Ortega I, 
Patino B, Arnan M, et al. Clinical efficacy and 
safety of primary antifungal prophylaxis with 
posaconazole vs itraconazole in allogeneic 
blood and marrow transplantation. Bone 
Marrow Transplant 2011;46:733–9 
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Athanasa
kis, 2013 
89 Clinical 
centers 
worldwide 
 
Proven or probable 
invasive fungal infection 
IFI 
 
According to consensus criteria of the 
European Organization for the 
Research and Treatment of Cancer and 
the Mycoses Study Group 
Cornely OA, Maertens J, Winston DJ, et al. 
Posaconazole vs. fluconazole or itraconazole 
prophylaxis in patients with neutropenia. N 
Engl J Med 2007;356:348-59 
Papadop
oulos, 
2013 
89 Clinical 
centers 
worldwide 
Proven or probable 
invasive fungal infection 
IFI 
 
According to consensus criteria of the 
European Organization for the 
Research and Treatment of Cancer and 
the Mycoses Study Group 
Cornely OA, Maertens J, Winston DJ, et al. 
Posaconazole vs. fluconazole or itraconazole 
prophylaxis in patients with neutropenia. N 
Engl J Med 2007;356:348-59 
de Vries, 
2006 
Hospital Occurrence of invasive 
fungal infection (candida 
or aspergillosis) during 
neutropenic state, which 
was assumed to be <1 year 
- (From 2 meta-analysis: (Rinaldi MG. Problems 
in the diagnosis of invasive fungal diseases. 
Rev Infect Dis 1991; 13: 493-5) + Kanda Y, 
Yamamoto R, Chizuka A, et al. Prophylactic 
action of oral fluconazole against fungal 
infection of neutropenic patients: a meta-
analysis of 16 randomized, controlled trials. 
Cancer 2000; 89: 1611-25)) 
Dranitsar
is, 2010 
89 Clinical 
centers 
worldwide 
Proven or probable 
invasive fungal infection 
IFI 
According to consensus criteria of the 
European Organization for the 
Research and Treatment of Cancer and 
the MycosesStudy Group 
Cornely OA, Maertens J, Winston DJ et al 
(2007) Posaconazole vs. fluconazole or 
itraconazole prophylaxis in patients with 
neutropenia. N Engl J Med 356:348–359 
Michalle
t, 2011 
89 Clinical 
centers 
worldwide 
Proven or probable 
invasive fungal infection 
IFI 
According to consensus criteria of the 
European Organization for the 
Research and Treatment of Cancer and 
the MycosesStudy Group 
Cornely OA, Maertens J, Winston DJ et al 
(2007) Posaconazole vs. fluconazole or 
itraconazole prophylaxis in patients with 
neutropenia. N Engl J Med 356:348–359 
Scharfste
in, 1997 
USA- 
endemic and 
non-endemic 
regions (not 
specified!) 
Efficacy of fluconazole 
prophylaxis in IFI 
A percentage reduction in the monthly 
probability of developing primary 
fungal infection (estimated as 70%) 
 
Powderly WG, Finkelstein D, Feinberg J, et al. 
A randomized trial comparing fluconazole with 
clotrimazole troches for the prevention of 
fungal infections in patients with advanced 
human immunodeficiency virus infection. N 
Engl J Med 1995; 332:700-5. 
Al-
Badriyeh
, 2010 
Major 
Australian 
tertiary 
Hospital 
Success The absence of initial antifungal 
discontinuation for the duration of the 
induction stage 
6 year (2003–09) retrospective chart review of 
AML patients 
Stam, 
2008 
89 Clinical 
centers 
worldwide 
Life years (no infection, 
breakthrough infection 
(invasive aspergillosis, 
Invasive candidiasis, 
others)) 
The expected life years per treatment 
arm were obtained by estimating the 
survival during as well as beyond the 
100-d prophylactic period. 
Cornely OA, Maertens J, Winston DJ et al 
(2007) Posaconazole vs. fluconazole or 
itraconazole prophylaxis in patients with 
neutropenia. N Engl J Med 356:348–359 
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de la 
Ca´mara, 
2009 
International
, multicenter 
clinical trial 
Survival It was assumed that if patients with 
acute GVHD survived the 112 day 
following initiation of prophylaxis, the 
death rate due to chronic GVHD may 
be applied as surviving acute GVHD 
puts a patient at high risk for chronic 
GVHD 
Ullmann AJ, Lipton JH, Vesole DH, 
Chandrasekar P, Langston A, Tarantolo SR et 
al. Posaconazole or fluconazole for prophylaxis 
in severe graft-versus-host disease. N Engl J 
Med 2007; 356: 335–347. 
O’Sulliv
an, 2012 
89 Clinical 
centers 
worldwide 
Probability of IFI, 
Probability of IFI-related 
death, Probability of death 
from other causes within 
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